101 results on '"Antigens, Bacterial adverse effects"'
Search Results
2. Bacterial Antigens Reduced the Inhibition Effect of Capsaicin on Cal 27 Oral Cancer Cell Proliferation.
- Author
-
Chakraborty R, Vickery K, Darido C, Ranganathan S, and Hu H
- Subjects
- Caspase 3 metabolism, Caspase 7 metabolism, Cell Line, Tumor, Cell Proliferation drug effects, Cell Survival drug effects, Gene Expression Regulation, Neoplastic drug effects, Humans, Lipopolysaccharides adverse effects, Mouth Neoplasms drug therapy, Mouth Neoplasms microbiology, Teichoic Acids adverse effects, Antigens, Bacterial adverse effects, Capsaicin pharmacology, Mouth Neoplasms metabolism, Signal Transduction drug effects
- Abstract
Oral cancer is a major global health problem with high incidence and low survival rates. The oral cavity contains biofilms as dental plaques that harbour both Gram-negative and Gram-positive bacterial antigens, lipopolysaccharide (LPS) and lipoteichoic acid (LTA), respectively. LPS and LTA are known to stimulate cancer cell growth, and the bioactive phytochemical capsaicin has been reported to reverse this effect. Here, we tested the efficacy of oral cancer chemotherapy treatment with capsaicin in the presence of LPS, LTA or the combination of both antigens. LPS and LTA were administered to Cal 27 oral cancer cells prior to and/or concurrently with capsaicin, and the treatment efficacy was evaluated by measuring cell proliferation and apoptotic cell death. We found that while capsaicin inhibits oral cancer cell proliferation and metabolism (MT Glo assay) and increases cell death (Trypan blue exclusion assay and Caspase 3/7 expression), its anti-cancer effect was significantly reduced on cells that are either primed or exposed to the bacterial antigens. Capsaicin treatment significantly increased oral cancer cells' suppressor of cytokine signalling 3 gene expression. This increase was reversed in the presence of bacterial antigens during treatment. Our data establish a rationale for clinical consideration of bacterial antigens that may interfere with the treatment efficacy of oral cancer.
- Published
- 2021
- Full Text
- View/download PDF
3. Trained Immunity-Based Vaccine in B Cell Hematological Malignancies With Recurrent Infections: A New Therapeutic Approach.
- Author
-
Ochoa-Grullón J, Benavente Cuesta C, González Fernández A, Cordero Torres G, Pérez López C, Peña Cortijo A, Conejero Hall L, Mateo Morales M, Rodríguez de la Peña A, Díez-Rivero CM, Rodríguez de Frías E, Guevara-Hoyer K, Fernández-Arquero M, and Sánchez-Ramón S
- Subjects
- Adult, Aged, Aged, 80 and over, Anti-Bacterial Agents therapeutic use, Antibodies, Bacterial blood, Antigens, Bacterial adverse effects, Bacterial Vaccines adverse effects, Female, Hematologic Neoplasms complications, Hematologic Neoplasms diagnosis, Humans, Immunity, Humoral, Immunoglobulin A blood, Immunoglobulin M blood, Male, Middle Aged, Pilot Projects, Reinfection, Respiratory Tract Infections diagnosis, Respiratory Tract Infections immunology, Respiratory Tract Infections microbiology, Retrospective Studies, Time Factors, Treatment Outcome, Vaccines, Combined adverse effects, Antigens, Bacterial administration & dosage, Bacterial Vaccines administration & dosage, Hematologic Neoplasms immunology, Respiratory Tract Infections prevention & control, Vaccines, Combined administration & dosage
- Abstract
Infectious complications are a major cause of morbidity and mortality in B-cell hematological malignancies (HM). Prophylaxis for recurrent infections in HM patients with antibody deficiency consists of first-line antibiotics and when unsuccessful, gammaglobulin replacement therapy (IgRT). Recent knowledge of trained immunity-based vaccines (TIbV), such as the sublingual polybacterial formulation MV130, has shown a promising strategy in the management of patients with recurrent infections. We sought to determine the clinical benefit of MV130 in a cohort of HM patients with recurrent respiratory tract infections (RRTIs) who underwent immunization with MV130 for 3 months. Clinical information included the frequency of infections, antibiotic use, number of visits to the GP and hospitalizations previous and after MV130 immunotherapy. Improvement on infection rate was classified as: clear (>60% reduction of infection), partial (26%-60%) and low (≤25%) improvement. Fifteen HM patients (aged 42 to 80 years; nine females) were included in the study. All patients reduced their infection rate. Analysis of paired data revealed that the median (range, min - max) of respiratory infectious rate significantly decreased from 4.0 (8.0-3.0) to 2.0 (4.0-0.0) ( p <0.001) at 12 months of MV130. A clear clinical improvement was observed in 53% (n = 8) of patients, partial improvement in 40% (n = 6) and low improvement in 7% (n = 1). These data correlated with a decrease on antibiotic consumption from 3.0 (8.0-1.0) to 1.0 (2.0-0.0) ( p = 0.002) during 12 months after initiation of treatment with MV130. The number of infectious-related GP or emergency room visits declined from 4.0 (8.0-2.0) to 2.0 (3.0-0.0) ( p <0.001), in parallel with a reduction in hospital admissions due to infections ( p = 0.032). Regarding safety, no adverse events were observed. On the other hand, immunological assessment of serum IgA and IgG levels demonstrated an increase in specific antibodies to MV130-contained bacteria following MV130 immunotherapy. In conclusion, MV130 may add clinical benefit reducing the rate of infections and enhancing humoral immune responses in these vulnerable patients., Competing Interests: LC and CD-R belong to the Immunotek R+D Department. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2021 Ochoa-Grullón, Benavente Cuesta, González Fernández, Cordero Torres, Pérez López, Peña Cortijo, Conejero Hall, Mateo Morales, Rodríguez de la Peña, Díez-Rivero, Rodríguez de Frías, Guevara-Hoyer, Fernández-Arquero and Sánchez-Ramón.)
- Published
- 2021
- Full Text
- View/download PDF
4. Clinical Implications of Difference in Antigenicity of Different Botulinum Neurotoxin Type A Preparations: Clinical Take-Home Messages from Our Research Pool and Literature.
- Author
-
Samadzadeh S, Ürer B, Brauns R, Rosenthal D, Lee JI, Albrecht P, and Hefter H
- Subjects
- Adult, Aged, Antigens, Bacterial administration & dosage, Bacterial Proteins administration & dosage, Botulinum Toxins, Type A administration & dosage, Cross-Sectional Studies, Female, Humans, Male, Middle Aged, Torticollis drug therapy, Torticollis immunology, Antibodies, Bacterial blood, Antibodies, Neutralizing blood, Antigens, Bacterial adverse effects, Bacterial Proteins adverse effects, Botulinum Toxins, Type A adverse effects, Torticollis blood
- Abstract
The three different botulinum toxin type A (BoNT/A) preparations being licensed in Europe and the U.S. differ in protein content, which seems to be a major factor influencing the antigenicity of BoNT/A. In the present study, several arguments out of our research pool were collected to demonstrate that the clinical response and antigenicity were different for the three BoNT/A preparations: some results of (1) a cross-sectional study on clinical outcome and antibody formation of 212 patients with cervical dystonia (CD) being treated between 2 and 22 years; 2) another cross-sectional study on the clinical aspects and neutralizing antibody (NAB) induction of 63 patients having developed partial secondary treatment under abobotulinum (aboBoNT/A) onabotulinumtoxin (onaBoNT/A) who were switched to incobotulinumtoxin (incoBoNT/A) in comparison to 32 patients being exclusively treated with incoBoNT/A. These results imply that (1) the presence of NAB cannot be concluded from the course of treatment, that (2) an increase in the dose and variability of outcome with treatment duration indicates the ongoing induction of NABs over time, that (3) the higher protein load of BoNT/A goes along with a higher incidence and prevalence of NAB induction and that (4) the best response to a BoNT/A is also dependent on the protein load of the preparation.
- Published
- 2020
- Full Text
- View/download PDF
5. A novel, safe, fast and efficient treatment for Her2-positive and negative bladder cancer utilizing an EGF-anthrax toxin chimera.
- Author
-
Jack S, Madhivanan K, Ramadesikan S, Subramanian S, Edwards DF 2nd, Elzey BD, Dhawan D, McCluskey A, Kischuk EM, Loftis AR, Truex N, Santos M, Lu M, Rabideau A, Pentelute B, Collier J, Kaimakliotis H, Koch M, Ratliff TL, Knapp DW, and Aguilar RC
- Subjects
- Administration, Intravesical, Animals, Antigens, Bacterial adverse effects, Antineoplastic Agents adverse effects, Apoptosis drug effects, Bacterial Toxins adverse effects, Cell Line, Tumor, Dogs, Drug Screening Assays, Antitumor, Epidermal Growth Factor adverse effects, Female, Humans, Immunotoxins adverse effects, Male, Mice, Primary Cell Culture, Receptor, ErbB-2 metabolism, Treatment Outcome, Urinary Bladder Neoplasms pathology, Urinary Bladder Neoplasms veterinary, Antigens, Bacterial administration & dosage, Antineoplastic Agents administration & dosage, Bacterial Toxins administration & dosage, Epidermal Growth Factor administration & dosage, Immunotoxins administration & dosage, Urinary Bladder Neoplasms drug therapy
- Abstract
Bladder cancer is the sixth most common cancer in the United States, and it exhibits an alarming 70% recurrence rate. Thus, the development of more efficient antibladder cancer approaches is a high priority. Accordingly, this work provides the basis for a transformative anticancer strategy that takes advantage of the unique characteristics of the bladder. Unlike mucin-shielded normal bladder cells, cancer cells are exposed to the bladder lumen and overexpress EGFR. Therefore, we used an EGF-conjugated anthrax toxin that after targeting EGFR was internalized and triggered apoptosis in exposed bladder cancer cells. This unique agent presented advantages over other EGF-based technologies and other toxin-derivatives. In contrast to known agents, this EGF-toxin conjugate promoted its own uptake via receptor microclustering even in the presence of Her2 and induced cell death with a LC
50 < 1 nM. Furthermore, our data showed that exposures as short as ≈3 min were enough to commit human (T24), mouse (MB49) and canine (primary) bladder cancer cells to apoptosis. Exposure of tumor-free mice and dogs with the agent resulted in no toxicity. In addition, the EGF-toxin was able to eliminate cells from human patient tumor samples. Importantly, the administration of EGF-toxin to dogs with spontaneous bladder cancer, who had failed or were not eligible for other therapies, resulted in ~30% average tumor reduction after one treatment cycle. Because of its in vitro and in vivo high efficiency, fast action (reducing treatment time from hours to minutes) and safety, we propose that this EGF-anthrax toxin conjugate provides the basis for new, transformative approaches against bladder cancer., (© 2019 UICC.)- Published
- 2020
- Full Text
- View/download PDF
6. Multifocal phlyctenular conjunctivitis in association with pulmonary tuberculosis.
- Author
-
Balyan M, Malhotra C, and Jain AK
- Subjects
- Antigens, Bacterial immunology, Child, Conjunctivitis, Allergic diagnosis, Conjunctivitis, Allergic immunology, Diagnosis, Differential, Eye Infections, Bacterial diagnosis, Eye Infections, Bacterial immunology, Female, Humans, Tuberculosis, Pulmonary microbiology, Antigens, Bacterial adverse effects, Conjunctiva pathology, Conjunctivitis, Allergic etiology, Eye Infections, Bacterial etiology, Mycobacterium tuberculosis immunology, Tuberculosis, Pulmonary complications
- Abstract
Competing Interests: None
- Published
- 2019
- Full Text
- View/download PDF
7. The N-end rule ubiquitin ligase UBR2 mediates NLRP1B inflammasome activation by anthrax lethal toxin.
- Author
-
Xu H, Shi J, Gao H, Liu Y, Yang Z, Shao F, and Dong N
- Subjects
- Animals, CRISPR-Cas Systems, Caspase 1 metabolism, Gene Knockout Techniques, HEK293 Cells, Humans, Inflammasomes drug effects, Macrophages metabolism, Mice, Protein Domains, Proteolysis drug effects, RAW 264.7 Cells, RNA, Small Interfering pharmacology, Ubiquitin-Conjugating Enzymes metabolism, Ubiquitination drug effects, Antigens, Bacterial adverse effects, Apoptosis Regulatory Proteins chemistry, Apoptosis Regulatory Proteins metabolism, Bacterial Toxins adverse effects, Macrophages drug effects, Ubiquitin-Protein Ligases chemistry, Ubiquitin-Protein Ligases metabolism
- Abstract
Anthrax lethal toxin (LT) is known to induce NLRP1B inflammasome activation and pyroptotic cell death in macrophages from certain mouse strains in its metalloprotease activity-dependent manner, but the underlying mechanism is unknown. Here, we establish a simple but robust cell system bearing dual-fluorescence reporters for LT-induced ASC specks formation and pyroptotic lysis. A genome-wide siRNA screen and a CRISPR-Cas9 knockout screen were applied to this system for identifying genes involved in LT-induced inflammasome activation. UBR2, an E3 ubiquitin ligase of the N-end rule degradation pathway, was found to be required for LT-induced NLRP1B inflammasome activation. LT is known to cleave NLRP1B after Lys44. The cleaved NLRP1B, bearing an N-terminal leucine, was targeted by UBR2-mediated ubiquitination and degradation. UBR2 partnered with an E2 ubiquitin-conjugating enzyme UBE2O in this process. NLRP1B underwent constitutive autocleavage before the C-terminal CARD domain. UBR2-mediated degradation of LT-cleaved NLRP1B thus triggered release of the noncovalent-bound CARD domain for subsequent caspase-1 activation. Our study illustrates a unique mode of inflammasome activation in cytosolic defense against bacterial insults., (© 2019 The Authors.)
- Published
- 2019
- Full Text
- View/download PDF
8. Safety and immunogenicity of the novel H4:IC31 tuberculosis vaccine candidate in BCG-vaccinated adults: Two phase I dose escalation trials.
- Author
-
Norrby M, Vesikari T, Lindqvist L, Maeurer M, Ahmed R, Mahdavifar S, Bennett S, McClain JB, Shepherd BM, Li D, Hokey DA, Kromann I, Hoff ST, Andersen P, de Visser AW, Joosten SA, Ottenhoff THM, Andersson J, and Brighenti S
- Subjects
- Acyltransferases administration & dosage, Acyltransferases adverse effects, Acyltransferases immunology, Adult, Antigens, Bacterial administration & dosage, Antigens, Bacterial adverse effects, Antigens, Bacterial immunology, Bacterial Proteins administration & dosage, Bacterial Proteins adverse effects, Bacterial Proteins immunology, CD4-Positive T-Lymphocytes immunology, Double-Blind Method, Drug Combinations, Drug-Related Side Effects and Adverse Reactions epidemiology, Drug-Related Side Effects and Adverse Reactions pathology, Finland, Healthy Volunteers, Humans, Oligodeoxyribonucleotides administration & dosage, Oligodeoxyribonucleotides adverse effects, Oligopeptides administration & dosage, Oligopeptides adverse effects, Placebos administration & dosage, Sweden, Treatment Outcome, Tuberculosis Vaccines administration & dosage, Tuberculosis prevention & control, Tuberculosis Vaccines adverse effects, Tuberculosis Vaccines immunology
- Abstract
Background: Novel vaccine strategies are required to provide protective immunity in tuberculosis (TB) and prevent development of active disease. We investigated the safety and immunogenicity of a novel TB vaccine candidate, H4:IC31 (AERAS-404) that is composed of a fusion protein of M. tuberculosis antigens Ag85B and TB10.4 combined with an IC31® adjuvant., Methods: BCG-vaccinated healthy subjects were immunized with various antigen (5, 15, 50, 150μg) and adjuvant (0, 100, 500nmol) doses of the H4:IC31 vaccine (n=106) or placebo (n=18) in two randomized, double-blind, placebo-controlled phase I studies conducted in a low TB endemic setting in Sweden and Finland. The subjects were followed for adverse events and CD4
+ T cell responses., Results: H4:IC31 vaccination was well tolerated with a safety profile consisting of mostly mild to moderate self-limited injection site pain, myalgia, arthralgia, fever and post-vaccination inflammatory reaction at the screening tuberculin skin test injection site. The H4:IC31 vaccine elicited antigen-specific CD4+ T cell proliferation and cytokine production that persisted 18weeks after the last vaccination. CD4+ T cell expansion, IFN-γ production and multifunctional CD4+ Th1 responses were most prominent after two doses of H4:IC31 containing 5, 15, or 50μg of H4 in combination with the 500nmol IC31 adjuvant dose., Conclusions: The novel TB vaccine candidate, H4:IC31, demonstrated an acceptable safety profile and was immunogenic, capable of triggering multifunctional CD4+ T cell responses in previously BCG-vaccinated healthy individuals. These dose-escalation trials provided evidence that the optimal antigen-adjuvant dose combinations are 5, 15, or 50μg of H4 and 500nmol of IC31., Trial Registration: ClinicalTrials.gov, NCT02066428 and NCT02074956., (Copyright © 2017 The Authors. Published by Elsevier Ltd.. All rights reserved.)- Published
- 2017
- Full Text
- View/download PDF
9. Farmer's Lung Disease. A Review.
- Author
-
Cano-Jiménez E, Acuña A, Botana MI, Hermida T, González MG, Leiro V, Martín I, Paredes S, and Sanjuán P
- Subjects
- Air Microbiology, Air Pollutants, Occupational adverse effects, Animal Feed microbiology, Antigens, Bacterial adverse effects, Antigens, Fungal adverse effects, Diagnosis, Differential, Diagnostic Techniques, Respiratory System, Food Storage methods, Humans, Humidity, Immunoglobulin G blood, Prognosis, Respiratory Protective Devices, Farmer's Lung diagnosis, Farmer's Lung epidemiology, Farmer's Lung etiology, Farmer's Lung prevention & control
- Abstract
Farmer's lung disease (FLD) is a form of hypersensitivity pneumonitis (HP) caused by inhaling microorganisms from hay or grain stored in conditions of high humidity in the agricultural workplace. It is probably underdiagnosed, especially in northern Spain, where climatic conditions favor the development of this disease. According to previous studies, the most common antigens are usually thermophilic actinomycetes and fungi. The epidemiology of the disease is not well known, and is based on studies conducted by Central European and Asian groups. The clinical presentation may vary, differentiating the chronic (exposure to lower concentrations of the antigen over a longer period time) and the acute forms (after exposure to high concentrations of the antigen). In patients with respiratory symptoms and agricultural occupational exposure, radiological, lung function and/or anatomical pathology findings must be compatible with FLD, bronchoalveolar lavage must show lymphocytosis, and tests must find sensitivity to the antigen. The main treatment is avoidance of the antigen, so it is essential to educate patients on preventive measures. To date, no controlled studies have assessed the role of immunosuppressive therapy in this disease. Corticosteroid treatment has only been shown to accelerate resolution of the acute forms, but there is no evidence that it is effective in preventing disease progression in the long-term or reducing mortality., (Copyright © 2016 SEPAR. Published by Elsevier Espana. All rights reserved.)
- Published
- 2016
- Full Text
- View/download PDF
10. A Phase 2, Randomized, Active-controlled, Observer-blinded Study to Assess the Immunogenicity, Tolerability and Safety of Bivalent rLP2086, a Meningococcal Serogroup B Vaccine, Coadministered With Tetanus, Diphtheria and Acellular Pertussis Vaccine and Serogroup A, C, Y and W-135 Meningococcal Conjugate Vaccine in Healthy US Adolescents.
- Author
-
Muse D, Christensen S, Bhuyan P, Absalon J, Eiden JJ, Jones TR, York LJ, Jansen KU, O'Neill RE, Harris SL, and Perez JL
- Subjects
- Antigens, Bacterial adverse effects, Bacterial Proteins adverse effects, Blood Bactericidal Activity, Child, Diphtheria-Tetanus-acellular Pertussis Vaccines adverse effects, Female, Healthy Volunteers, Humans, Male, Meningococcal Vaccines adverse effects, Single-Blind Method, Treatment Outcome, United States, Antibodies, Bacterial blood, Antigens, Bacterial administration & dosage, Antigens, Bacterial immunology, Bacterial Proteins administration & dosage, Bacterial Proteins immunology, Diphtheria-Tetanus-acellular Pertussis Vaccines administration & dosage, Diphtheria-Tetanus-acellular Pertussis Vaccines immunology, Meningococcal Vaccines administration & dosage, Meningococcal Vaccines immunology
- Abstract
Background: Bivalent rLP2086, targeting meningococcal serogroup B, will extend prevention of meningococcal disease beyond that provided by quadrivalent serogroup ACWY vaccines; coadministration with recommended vaccines may improve adherence to vaccine schedules. This phase 2, randomized, active-controlled, observer-blinded study assessed whether immune responses induced by coadministration of Menactra (meningococcal A, C, Y and W-135 polysaccharide conjugate vaccine [MCV4]) and Adacel (tetanus toxoid, reduced diphtheria toxoid, acellular pertussis vaccine [Tdap]) with bivalent rLP2086 (Trumenba [meningococcal serogroup B vaccine], approved in the United States) were noninferior to MCV4 + Tdap or bivalent rLP2086 alone., Methods: Healthy adolescents aged 10 to <13 years received MCV4 + Tdap + bivalent rLP2086, MCV4 + Tdap or bivalent rLP2086. Bivalent rLP2086 response was assessed with serum bactericidal assays using human complement with 2 meningococcal serogroup B test strains expressing vaccine-heterologous factor H-binding protein variants; MCV4 with SBAs using rabbit complement; and Tdap with multiplexed Luminex assays. Safety was evaluated., Results: Two thousand six hundred forty-eight subjects were randomized. Immune responses to MCV4 + Tdap + bivalent rLP2086 were noninferior to MCV4 + Tdap or bivalent rLP2086 alone. Seroprotective serum bactericidal assays using human complement titers were documented for 62.3%-68.0% and 87.5%-90% of MCV4 + Tdap + bivalent rLP2086 recipients after doses 2 and 3, respectively. A ≥4-fold rise in serum bactericidal assays using human complement titers from baseline was achieved by 56.3%-64.3% and 84.0%-85.7% of subjects after doses 2 and 3, respectively. Bivalent rLP2086 alone induced similar responses. Concomitant administration did not substantially increase reactogenicity compared with bivalent rLP2086 alone., Conclusions: Bivalent rLP2086 given concomitantly with MCV4 + Tdap met all noninferiority immunogenicity criteria without a clinically meaningful increase in reactogenicity. MCV4 and bivalent rLP2086 coadministration would provide coverage against the 5 major disease-causing serogroups.
- Published
- 2016
- Full Text
- View/download PDF
11. [Chronic Farmer's lung disease with emphysema].
- Author
-
Soumagne T, Degano B, and Dalphin JC
- Subjects
- Adult, Airway Obstruction etiology, Allergens adverse effects, Alveolitis, Extrinsic Allergic classification, Alveolitis, Extrinsic Allergic etiology, Alveolitis, Extrinsic Allergic pathology, Alveolitis, Extrinsic Allergic physiopathology, Animal Feed adverse effects, Animal Feed microbiology, Animals, Antigens, Bacterial adverse effects, Antigens, Fungal adverse effects, Disease Progression, Dust, Farmer's Lung diagnosis, Fibrosis, Housing, Animal, Humans, Male, Occupational Exposure, Prognosis, Pulmonary Emphysema diagnosis, Respiratory Function Tests, Ventilation, Farmer's Lung complications, Pulmonary Emphysema etiology
- Abstract
Introduction: Farmer's lung (FL) is the most common type of hypersensitivity pneumonitis (HP), with an estimated prevalence of between 0.5 and 1.5% in dairy farmers. In chronic FL, fibrotic sequelae are widely described in the literature although our experience and occasional epidemiological studies emphasize an increased risk of developing emphysema in these patients., Case Report: We report a case of FL in a 37-year-old patient with typical clinical features (exertional dyspnoea, lymphocytic alveolitis and computed tomography appearances) together with proven allergen exposure. This patient developed early pulmonary emphysema probably due to intermittent massive exposure to antigens and to bacterial and fungal micro-organisms., Conclusion: The current classification of HP differentiates acute, subacute and chronic forms but does not take account of the role of the mode of exposure and the evolution of the disease. The prognosis and evolution of HP seem to be dependent on the type and pattern of exposure. A new classification with two clusters has been suggested: in type 1, massive and intermittent exposure, as in FL, may lead to emphysema with chronic airflow obstruction and, in type 2, chronic exposure to a low level, as in bird fanciers, may lead to fibrosis with a restrictive pattern., (Copyright © 2014 SPLF. Published by Elsevier Masson SAS. All rights reserved.)
- Published
- 2015
- Full Text
- View/download PDF
12. Therapeutic effect of methotrexate encapsulated in cationic liposomes (EndoMTX) in comparison to free methotrexate in an antigen-induced arthritis study in vivo.
- Author
-
Gottschalk O, Metz P, Dao Trong ML, Altenberger S, Jansson V, Mutschler W, and Schmitt-Sody M
- Subjects
- Administration, Intravenous, Animals, Antigens, Bacterial adverse effects, Arthritis, Experimental chemically induced, Arthritis, Experimental pathology, Arthritis, Rheumatoid pathology, Blood Platelets pathology, Capsules, Cell Communication physiology, Disease Models, Animal, Endothelial Cells pathology, Female, Knee Joint blood supply, Knee Joint diagnostic imaging, Knee Joint pathology, Leukocytes pathology, Liposomes, Mice, Mice, Inbred C57BL, Microcirculation physiology, Radiography, Treatment Outcome, Antirheumatic Agents administration & dosage, Antirheumatic Agents therapeutic use, Arthritis, Experimental drug therapy, Arthritis, Rheumatoid drug therapy, Arthritis, Rheumatoid immunology, Methotrexate administration & dosage, Methotrexate therapeutic use
- Abstract
Objectives: Cationic lipid complexes bind to angiogenic endothelial cells of solid tumours and microvessels of chronic inflammatory tissue. Methotrexate (MTX) is one of the drugs used in the therapy of rheumatoid arthritis (RA); it is applied systemically but can have serious side-effects. The aim of this study was to investigate the impact of MTX encapsulated in cationic liposomes (EndoMTX) in comparison to treatment with free MTX., Method: We used an antigen-induced arthritis (AiA) model and investigated the leucocyte- and platelet-endothelial cell interaction in arthritic female C57/Bl6 mice and in healthy controls. The arthritic animals were divided into four different groups receiving either trehalose, free MTX, EndoMTX placebo, or EndoMTX. These parameters and functional capillary density (FCD) were measured and assessed by intravital microscopy (IVM). We controlled clinical parameters such as the knee joint diameter (KJD) throughout the observation period., Results: Animals treated with EndoMTX showed a significant and superior reduction in leucocyte- and platelet-endothelial cell interaction, FCD, and KJD. Free MTX or empty liposomes also showed a reduction in these parameters but not to a significant level. FCD decreased in the EndoMTX group in comparison to using free drugs or empty carrier-like liposomes., Conclusions: This study demonstrates the advantage of using MTX encapsulated in cationic liposomes in contrast to free and generic MTX, with a higher efficacy in anti-inflammatory and anti-angiogenic abilities. Targeting with cationic liposomes may be a promising treatment option and should be elucidated in further experiments regarding dose reduction and side-effects due to MTX usage.
- Published
- 2015
- Full Text
- View/download PDF
13. Induction Murine Models of Chronic Fatigue Syndrome by Brucella abortus Antigen Injections: Is Anemia Induced or Not?
- Author
-
Moriya J, He Q, Uenishi H, Akazawa S, Yamakawa J, Kobayashi J, and Ishigaki Y
- Subjects
- Anemia physiopathology, Animals, Antigens, Bacterial administration & dosage, Antigens, Bacterial chemistry, Behavior, Animal, Female, Injections, Mice, Mice, Inbred BALB C, Anemia chemically induced, Antigens, Bacterial adverse effects, Brucella abortus chemistry, Disease Models, Animal, Fatigue Syndrome, Chronic chemically induced
- Abstract
To investigate whether Brucella abortus (BA) antigen injections lead to anemia, and to establish an appropriate Chronic Fatigue Syndrome (CFS) animal model by BA injections, 6 repeated injections of BA antigen were fulfilled every 2 weeks. At a high dose of 1∗10(10) particles/mouse, anemia was induced within 2 weeks and then recovered a lot at the end of the research, while at a moderate dose of 1∗10(8) (3 injections) shifting to 1∗10(9)/mouse (3 injections) anemia was absent. In both groups running wheel activity remained very low even 6 weeks after the last injection.
- Published
- 2015
- Full Text
- View/download PDF
14. Safety and efficacy assessment of two new leprosy skin test antigens: randomized double blind clinical study.
- Author
-
Rivoire BL, Groathouse NA, TerLouw S, Neupane KD, Ranjit C, Sapkota BR, Khadge S, Kunwar CB, Macdonald M, Hawksworth R, Thapa MB, Hagge DA, Tibbals M, Smith C, Dube T, She D, Wolff M, Zhou E, Makhene M, Mason R, Sizemore C, and Brennan PJ
- Subjects
- Adolescent, Adult, Antigens, Bacterial administration & dosage, Antigens, Bacterial immunology, Double-Blind Method, Female, Humans, Leprosy immunology, Male, Middle Aged, Mycobacterium leprae immunology, Sensitivity and Specificity, Young Adult, Antigens, Bacterial adverse effects, Leprosy diagnosis, Skin Tests adverse effects, Skin Tests methods
- Abstract
Background: New tools are required for the diagnosis of pre-symptomatic leprosy towards further reduction of disease burden and its associated reactions. To address this need, two new skin test antigens were developed to assess safety and efficacy in human trials., Methods: A Phase I safety trial was first conducted in a non-endemic region for leprosy (U.S.A.). Healthy non-exposed subjects (n = 10) received three titrated doses (2.5 µg, 1.0 µg and 0.1 µg) of MLSA-LAM (n = 5) or MLCwA (n = 5) and control antigens [Rees MLSA (1.0 µg) and saline]. A randomized double blind Phase II safety and efficacy trial followed in an endemic region for leprosy (Nepal), but involved only the 1.0 µg (high dose) and 0.1 µg (low dose) of each antigen; Tuberculin PPD served as a control antigen. This Phase II safety and efficacy trial consisted of three Stages: Stage A and B studies were an expansion of Phase I involving 10 and 90 subjects respectively, and Stage C was then conducted in two parts (high dose and low dose), each enrolling 80 participants: 20 borderline lepromatous/lepromatous (BL/LL) leprosy patients, 20 borderline tuberculoid/tuberculoid (BT/TT) leprosy patients, 20 household contacts of leprosy patients (HC), and 20 tuberculosis (TB) patients. The primary outcome measure for the skin test was delayed type hypersensitivity induration., Findings: In the small Phase I safety trial, reactions were primarily against the 2.5 µg dose of both antigens and Rees control antigen, which were then excluded from subsequent studies. In the Phase II, Stage A/B ramped-up safety study, 26% of subjects (13 of 50) showed induration against the high dose of each antigen, and 4% (2 of 50) reacted to the low dose of MLSA-LAM. Phase II, Stage C safety and initial efficacy trial showed that both antigens at the low dose exhibited low sensitivity at 20% and 25% in BT/TT leprosy patients, but high specificity at 100% and 95% compared to TB patients. The high dose of both antigens showed lower specificity (70% and 60%) and sensitivity (10% and 15%). BL/LL leprosy patients were anergic to the leprosy antigens., Interpretation: MLSA-LAM and MLCwA at both high (1.0 µg) and low (0.1 µg) doses were found to be safe for use in humans without known exposure to leprosy and in target populations. At a sensitivity rate of 20-25% these antigens are not suitable as a skin test for the detection of the early stages of leprosy infection; however, the degree of specificity is impressive given the presence of cross-reactive antigens in these complex native M. leprae preparations., Trial Registration: ClinicalTrials.gov NCT01920750 (Phase I), NCT00128193 (Phase II).
- Published
- 2014
- Full Text
- View/download PDF
15. Efficacy and safety of recombinant Mycobacterium tuberculosis ESAT-6 protein for diagnosis of pulmonary tuberculosis: a phase II trial.
- Author
-
Sun QF, Xu M, Wu JG, Chen BW, Du WX, Ding JG, Shen XB, Su C, Wen JS, and Wang GZ
- Subjects
- Adult, Analysis of Variance, Area Under Curve, China, Dose-Response Relationship, Drug, Female, Humans, Male, Middle Aged, ROC Curve, Skin Tests, Antigens, Bacterial adverse effects, Antigens, Bacterial genetics, Bacterial Proteins adverse effects, Bacterial Proteins genetics, Recombinant Proteins adverse effects, Recombinant Proteins genetics, Tuberculosis, Pulmonary diagnosis
- Abstract
Background: This study aimed to determine the efficacy and safety of recombinant Mycobacterium tuberculosis ESAT-6 protein for diagnosis of pulmonary tuberculosis (TB)., Material and Methods: A phase II trial was performed in 158 patients with pulmonary TB (145 initially-treated and 13 re-treated) and 133 healthy subjects. Skin testing was carried out by injecting purified protein derivative (PPD) (on left forearm) or recombinant ESAT-6 protein at a dosage of 2, 5, or 10 μg/mL (on the right forearm) in each subject. Reaction activity and adverse events were monitored at 24, 48, and 72 h following the injection. Receiver operating characteristic curves were plotted to determine the areas under the curves (AUCs) and the cut-off induration diameters for the optimal diagnostic performance., Results: The reaction activity was significantly increased upon recombinant ESAT-6 injection in pulmonary TB patients compared with healthy subjects. In pulmonary TB patients, the reaction was dose-dependent, and at 48 h, 10 μg/mL recombinant ESAT-6 produced a reaction similar to that produced by PPD. The AUCs for a 10 μg/mL dosage were 0.9823, 0.9552, and 0.9266 for 24 h, 48 h, and 72 h, respectively, and the induration diameters of 4.5-5.5 mm were the optimal trade-off values between true positive rates and false positive rates. No serious adverse events occurred in any subjects., Conclusions: Recombinant ESAT-6 protein is efficacious and safe for diagnosing pulmonary TB. Based on the reaction, performance, safety, and practicability, we recommend that 10 μg/mL at 48 h with an induration cut-off value of 5.0 mm be used.
- Published
- 2013
- Full Text
- View/download PDF
16. [Preclinical studies of an adsorbed diphtheria-tetanus-pertussis vaccine (ADTP-vaccine) with acellular pertussis component].
- Author
-
Zaĭtsev EM, Britsina MV, Bazhanova IG, Mertsalova NU, Ozeretskovskaia MN, Ermolova EV, Plekhanova NG, Mikhaĭlova NA, Kolyshkin VA, and Zverev VV
- Subjects
- Adjuvants, Immunologic pharmacology, Aluminum Hydroxide adverse effects, Animals, Antigens, Bacterial adverse effects, Antigens, Bacterial immunology, Diphtheria Toxin immunology, Diphtheria-Tetanus-acellular Pertussis Vaccines adverse effects, Diphtheria-Tetanus-acellular Pertussis Vaccines immunology, Drug Evaluation, Preclinical, Female, Guinea Pigs, Humans, Male, Meningoencephalitis immunology, Mice, Tetanus Toxin immunology, Adjuvants, Immunologic adverse effects, Aluminum Hydroxide pharmacology, Antigens, Bacterial pharmacology, Bordetella pertussis, Diphtheria Toxin toxicity, Diphtheria-Tetanus-acellular Pertussis Vaccines pharmacology, Meningoencephalitis prevention & control, Tetanus Toxin toxicity
- Abstract
Aim: Evaluate standardness of antigenic composition of pertussis component, completeness of sorption of pertussis, diphtheria and tetanus components, specific activity and safety of experimental series ofADTP-vaccine with acellular pertussis component (ADTaP-vaccine)., Materials and Methods: The content of separate antigens (pertussis toxin, filamentous hemagglutinin and agglutinogens 1, 2, 3) in samples of acellular pertussis component of ADTaP-vaccine and completeness of sorption of pertussis component of ADTaP-vaccine were evaluated by using enzyme immunoassay. Completeness of sorption of diphtheria and tetanus components were determined in flocculation reaction and antitoxin-binding reactions, respectively. Protective activity ofADTaP-vaccine was studied in model ofmeningoencephalitis development in mice infected with Bordetella pertussis (strain 18323) neurotropic virulent culture, protective activity oftetanus component - by survival of mice after administration of tetanus toxin, protective activity of diphtheria component - by survival of guinea pigs after administration of diphtheria toxin. Safety of preparations was evaluated in tests of acute and chronic toxicity with carrying out pathomorphologic studies including immature animals., Results: All the studied experimental series ofADTaP-vaccine were standard by content of separate antigens of pertussis microbe. All the ADTaP-vaccine components were completely sorbed on aluminium hydroxide gel. By protective activity ADTaP preparations satisfied the WHO requirements. The preparations were non-toxic in acute and chronic toxicity and did not induce pathomorphologic changes including immature animals., Conclusion: Experimental samples of ADTaP-vaccine by specific activity and safety satisfied WHO requirements.
- Published
- 2013
17. Soluble TRAIL in normal pregnancy and acute pyelonephritis: a potential explanation for the susceptibility of pregnant women to microbial products and infection.
- Author
-
Chaemsaithong P, Romero R, Korzeniewski SJ, Schwartz AG, Stampalija T, Dong Z, Yeo L, Hernandez-Andrade E, Hassan SS, and Chaiworapongsa T
- Subjects
- Acute Disease, Adolescent, Adult, Antigens, Bacterial adverse effects, Antigens, Bacterial blood, Antigens, Viral adverse effects, Antigens, Viral blood, Bacterial Infections complications, Case-Control Studies, Cross-Sectional Studies, Disease Susceptibility blood, Female, Humans, Pregnancy, Pregnancy Complications, Infectious etiology, Pyelonephritis etiology, Young Adult, Bacterial Infections blood, Pregnancy Complications, Infectious blood, Pyelonephritis blood, TNF-Related Apoptosis-Inducing Ligand blood
- Abstract
Objective: Pregnancy is characterized by activation of the innate immune response demonstrated by phenotypic and metabolic changes in granulocytes and monocytes. This state of activation has been implicated in the pathophysiology of multiorgan dysfunction of pregnant women with acute viral or bacterial infection. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is one of the mediators responsible for neutrophil apoptosis. Gene deletion of TRAIL results in delayed neutrophil apoptosis and resolution of inflammation after the administration of bacterial endotoxin. The aim of this study was to determine whether maternal plasma concentrations of the soluble form of TRAIL (sTRAIL) differ in women with uncomplicated pregnancy and those with acute pyelonephritis., Method: A cross-sectional study was conducted to include women in the following groups: (1) non-pregnant (n = 23); (2) uncomplicated pregnancies (n = 93) and (3) pregnancies with acute pyelonephritis (n = 23). Plasma concentrations of sTRAIL were determined by enzyme-linked immunoassay., Results: (1) Women with uncomplicated pregnancies had a lower mean plasma sTRAIL concentration (pg/mL) than non-pregnant women (31.5 ± 10.1 versus 53.3 ± 12.5; p < 0.001); (2) plasma sTRAIL concentrations did not change as a function of gestational age (Pearson correlation = -0.1; p = 0.4); (3) the mean plasma sTRAIL concentration (pg/mL) was significantly lower in pregnant women with acute pyelonephritis than in those with uncomplicated pregnancies (20.5 ± 6.6 versus 31.5 ± 10.1; p < 0.001) and (4) among patients with acute pyelonephritis, patients with bacteremia had a significantly lower mean plasma concentration of sTRAIL (pg/mL) than those without bacteremia (15.1 ± 4.8 versus 24.7 ± 4.6; p < 0.001)., Conclusion: Women with uncomplicated pregnancies are associated with a significantly lower mean maternal plasma concentration of sTRAIL than that observed in non-pregnant women. Moreover, a further decrease in plasma sTRAIL concentration was observed in pregnant women with acute pyelonephritis, and this could account, at least in part, for the exaggerated intravascular inflammatory response previously reported in pyelonephritis during pregnancy.
- Published
- 2013
- Full Text
- View/download PDF
18. Safety evaluation of a thermolysin enzyme produced from Geobacillus stearothermophilus.
- Author
-
Ke Q, Chen A, Minoda M, and Yoshida H
- Subjects
- Allergens administration & dosage, Allergens adverse effects, Animals, Antigens, Bacterial administration & dosage, Antigens, Bacterial adverse effects, Bacterial Proteins administration & dosage, Cell Line, Cricetinae, Cricetulus, Female, Food Additives administration & dosage, Geobacillus stearothermophilus immunology, Male, Mice, Mice, Inbred Strains, Micronucleus Tests, Mutagenicity Tests, No-Observed-Adverse-Effect Level, Rats, Rats, Sprague-Dawley, Rats, Wistar, Thermolysin administration & dosage, Toxicity Tests, Acute, Toxicity Tests, Subchronic, Bacterial Proteins adverse effects, Food Additives adverse effects, Geobacillus stearothermophilus enzymology, Thermolysin adverse effects
- Abstract
Thermolysin is a zinc metalloprotease that has potential uses in the food industry. The safety of thermolysin has not been demonstrated before, and therefore a series of standard toxicological tests to assess its potential toxicity was undertaken. The thermolysin used in this study was derived from the thermophilic bacterium Geobacillus stearothermophilus, which had undergone chemical mutagenesis to generate strains with increased thermolysin production. Acute toxicity studies in rats and mice showed that thermolysin powder is not acutely toxic with an oral LD₅₀ of more than 18,000 mg/kg (2520 mg/kg thermolysin protein) in rats and more than 24,000 mg/kg (3360 mg/kg protein) in mice. Subchronic feeding studies in rats for 91 days at doses up to 1000 mg/kg (390 mg/kg protein) revealed no significant differences between treated and non-treated groups and a No Observed Effect Level (NOEL) of 1000 mg/kg (390 mg/kg protein) per day was established. Results from genotoxicity tests such as in vitro chromosomal aberration assay and in vivo mouse micronucleus were negative. Allergenicity sequence analysis revealed no evidence suggesting that thermolysin is an allergen. The data presented in this study support the conclusion that thermolysin is safe for use in food production., (Copyright © 2013 Elsevier Ltd. All rights reserved.)
- Published
- 2013
- Full Text
- View/download PDF
19. Vaccination efficiency of surface antigens and killed whole cell of Pseudomonas putida in large yellow croaker (Pseudosciaena crocea).
- Author
-
Mao Z, Ye J, Li M, Xu H, and Chen J
- Subjects
- Animals, Antigens, Bacterial administration & dosage, Antigens, Surface administration & dosage, Antigens, Surface adverse effects, Bacterial Outer Membrane Proteins physiology, Bacterial Vaccines administration & dosage, Fish Diseases immunology, Fish Diseases microbiology, Immunity, Innate, Lipopolysaccharides physiology, Polysaccharides, Bacterial physiology, Pseudomonas Infections immunology, Pseudomonas Infections microbiology, Pseudomonas Infections prevention & control, Vaccination veterinary, Antigens, Bacterial adverse effects, Bacterial Vaccines adverse effects, Fish Diseases prevention & control, Perciformes, Pseudomonas Infections veterinary, Pseudomonas putida immunology
- Abstract
Large yellow croaker (Pseudosciaena crocea), a major marine fish aquacultured in the southeastern coastal region of China, has become endangered by the pathogen Pseudomonas putida in recent years. P. putida infections occur in low water temperatures when fish reduce food intake, thus oral antibiotic administration is not practical. Therefore, vaccination may be the only method to prevent the infection. In the present study, main surface antigens of P. putida, including lipopolysaccharide (LPS), outer membrane proteins (OMP), extracellular biofilm polysaccharide (EPS), and formalin-killed cell (FKC) bacterin, were prepared and the fish vaccinated. On post-immunization day 28, serum antibody titers, phagocytic responses of leukocytes, and lysozyme activities of the fish were evaluated. The efficiency of vaccination was tested by artificial challenge via intraperitoneal injection of live bacteria on post-immunization day 28 and 35, respectively. The results showed that although significant humoral and innate immune responses were elicited in all vaccination groups, the challenge produced similar poor protection in both tests, with a relative percent survival (RPS) of 0-40%. Although the EPS group showed a complete lack of protection, LPS reached the highest RPS value (40%), suggesting that LPS may be involved in protection immunity against the pathogen. Further analysis of the ultra-structures of tissues from infected fish via TEM revealed macrophage survival and intracellular replication ability of the pathogen. New strategies for development might put more emphasis on efficient clearance of intracellular bacteria. The present study is the first to report vaccination against the fish pathogen P. putida and the first investigation of intracellular survival of this pathogen in host macrophages., (Copyright © 2013 Elsevier Ltd. All rights reserved.)
- Published
- 2013
- Full Text
- View/download PDF
20. Preclinical study and phase I clinical safety evaluation of recombinant Mycobacterium tuberculosis ESAT6 protein.
- Author
-
Du WX, Chen BW, Lu JB, Gao MQ, Shen XB, Yang L, Su C, Wang GZ, Sun QF, and Xu M
- Subjects
- Adult, Aged, Animals, Antigens, Bacterial administration & dosage, Bacterial Proteins administration & dosage, Dose-Response Relationship, Immunologic, Drug Evaluation, Preclinical, Female, Guinea Pigs, Humans, Immunization, Male, Middle Aged, Recombinant Proteins administration & dosage, Tuberculin immunology, Tuberculin Test, Young Adult, Antigens, Bacterial adverse effects, Antigens, Bacterial immunology, Bacterial Proteins adverse effects, Bacterial Proteins immunology, Recombinant Proteins adverse effects, Recombinant Proteins immunology
- Abstract
Background: To investigate the ability of rESAT6 to identify different mycobacteria-sensitized guinea pigs and its safety in preclinical and phase I clinical study., Material and Methods: Guinea pigs were sensitized with different Mycobacteria. After sensitization, all animals were intradermally injected with rESAT6 and either PPD or PPD-B. At 24 h after the injection, the erythema of the injection sites were measured using a double-blind method. For the preclinical safety study, different doses of rESAT6 and BSA were given 3 times intramuscularly to guinea pigs. On day 14 after the final immunization, the guinea pigs were intravenously injected with the same reagents in the hind legs and the allergic reactions were observed. A single-center, randomized, open phase I clinical trial was employed. The skin test was conducted in 32 healthy volunteers aged 19-65 years with 0.1 µg, 0.5 µg, and 1 µg rESAT6. Physical examination and laboratory tests were performed before and after the skin test and adverse reactions were monitored. The volunteers' local and systemic adverse reactions and adverse events were recorded for 7 days., Results: Positive PPD or PPD-B skin tests were observed in all Mycobacteria-sensitized guinea pigs; the diameters of erythema were all >10 mm. The rESAT6 protein induced a positive skin test result in the guinea pigs sensitized with MTB, M. bovis, M. africanum and M. kansasii; the diameters of erythema were 14.7±2.0, 9.3±3.8, 18.7±2.4, and 14.8±4.2 mm, respectively. A negative skin test result was detected in BCG-vaccinated and other NTM-sensitized guinea pigs. The rESAT6 caused no allergic symptoms, but many allergic reactions, such as cough, dyspnea, and even death, were observed in the guinea pigs who were administered BSA. During the phase I clinical trial, no adverse reactions were found in the 0.1 µg rESAT6 group, but in the 0.5 µg rESAT6 group 2 volunteers reported pain and 1 reported itching, and in the 1 µg rESAT6 group there was 1 case of pain, 1 case of itching, and 1 case of blister. No other local or systemic adverse reactions or events were reported., Conclusions: The rESAT6 can differentiate effectively among MTB infection, BCG vaccination, and NTM infection and is safe in healthy volunteers.
- Published
- 2013
- Full Text
- View/download PDF
21. Randomised clinical trial investigating the specificity of a novel skin test (C-Tb) for diagnosis of M. tuberculosis infection.
- Author
-
Aggerbeck H, Giemza R, Joshi P, Tingskov PN, Hoff ST, Boyle J, Andersen P, and Lewis DJ
- Subjects
- Adolescent, Adult, Antigens, Bacterial adverse effects, Antigens, Bacterial chemistry, Antigens, Bacterial immunology, Bacterial Proteins adverse effects, Bacterial Proteins chemistry, Bacterial Proteins immunology, Dose-Response Relationship, Immunologic, Female, Humans, Male, Middle Aged, Mycobacterium bovis immunology, Mycobacterium tuberculosis immunology, Phenol chemistry, Sensitivity and Specificity, Tuberculin Test adverse effects, Vaccination, Young Adult, Mycobacterium tuberculosis physiology, Tuberculin Test methods, Tuberculosis diagnosis, Tuberculosis immunology
- Abstract
Background: Tuberculin skin testing is simple and relatively inexpensive, but the specificity of PPD is affected by BCG vaccination., Objective: Determine optimal dose and specificity of recombinant ESAT-6 and CFP-10 (C-Tb) produced in Lactococcus lactis for diagnosis of M. tuberculosis infection., Methods: In a dose finding phase I trial 0.01 or 0.1 µg preserved and unpreserved C-Tb was injected by Mantoux technique in 38 patients with active tuberculosis and induration responses measured. In a phase II specificity trial in 151 uninfected, BCG vaccinated participants 0.1 µg C-Tb was compared to 2 TU PPD., Results: 0.1 µg C-Tb gave a median induration of 15 mm after 2 days. Phenol preservation did not affect the response. The specificity of C-Tb was 99.3% (95% CI 96-100%) regarding indurations ≥5 mm as a positive outcome. This was higher than the specificity of PPD (63% using a cut-off of 5 mm or 92% using a cut-off of 15 mm to adjust for non-specific BCG responses). Local adverse reactions following C-Tb injection included transient itching and discomfort as expected components of the immune response., Conclusion: C-Tb offers a simple and convenient skin test to diagnose M. tuberculosis infection using a single, universal cut-off unaffected by BCG vaccination., Trial Registration: ClinicalTrials.gov NCT01033929 and NCT01241188.
- Published
- 2013
- Full Text
- View/download PDF
22. Evaluation of specific immune responses to BoNT/A and tetanus toxoid in patients undergoing treatment for neurologic disorders.
- Author
-
Vlata Z, Tsatsakis A, Tzagournissakis M, and Krambovitis E
- Subjects
- Antibodies, Bacterial analysis, Antibodies, Bacterial biosynthesis, Antibodies, Neutralizing analysis, Antigens, Bacterial administration & dosage, Antigens, Bacterial immunology, Antigens, Bacterial therapeutic use, Bacterial Vaccines immunology, Botulinum Toxins, Type A administration & dosage, Botulinum Toxins, Type A immunology, Botulinum Toxins, Type A therapeutic use, Cell Proliferation drug effects, Cells, Cultured, Cross Reactions, Cross-Priming, Dose-Response Relationship, Immunologic, Humans, Leukocyte Common Antigens metabolism, Leukocytes, Mononuclear cytology, Leukocytes, Mononuclear drug effects, Lymphocyte Activation drug effects, Nervous System Diseases blood, Nervous System Diseases drug therapy, Neuromuscular Agents administration & dosage, Neuromuscular Agents adverse effects, Neuromuscular Agents immunology, Neuromuscular Agents therapeutic use, Neurotoxins administration & dosage, Neurotoxins adverse effects, Neurotoxins immunology, Neurotoxins therapeutic use, Pilot Projects, T-Lymphocytes drug effects, T-Lymphocytes immunology, T-Lymphocytes metabolism, Antibodies, Neutralizing biosynthesis, Antigens, Bacterial adverse effects, Botulinum Toxins, Type A adverse effects, Immunity, Active drug effects, Leukocytes, Mononuclear immunology, Metalloendopeptidases immunology, Nervous System Diseases immunology, Tetanus Toxin immunology
- Abstract
Botulinum neurotoxins (BoNTs) are used in the treatment of many neurological disorders. The primary structure of BoNTs shows a high degree of homology with the tetanus neurotoxin, the toxoid of which is used as a vaccine. Because of the potential cross-reactivity between these toxins, we investigated the effects of Botulinum neurotoxin A (BoNT/A) and tetanus toxoid on peripheral blood mononuclear cells (PBMC) and the corresponding serum antibody levels, in twenty patients who had been treated with BoNT/A. We observed very low PBMC immunostimulation by BoNT/A at the tested dose (15 units/ml), as demonstrated by the low lymphocyte proliferation, and the absence of detectable antibodies cross-reacting with tetanus. However, exposure of PBMC from tetanus-sensitized patients to both neurotoxins showed that BoNT/A exerted a co stimulatory effect on tetanus-stimulated cells. Interestingly, in flow cytometry analysis, BoNT/A seemed to also alter the ratio of naïve (CD45RA) : memory/effector (CD45RO) T lymphocyte subsets, in favour of CD45RO. These preliminary data give a new insight on the potential immune crossreactivity between the two antigens. In view of the wide use of both neurotoxins, these immunotoxic effects merit a more detailed investigation.
- Published
- 2012
- Full Text
- View/download PDF
23. The effects of Mycobacteria vaccae derivative on allergen-specific responses in children with atopic dermatitis.
- Author
-
Dunstan JA, Brothers S, Bauer J, Hodder M, Jaksic MM, Asher MI, and Prescott SL
- Subjects
- Adolescent, Animals, Antigens, Bacterial adverse effects, Antigens, Dermatophagoides immunology, Cells, Cultured, Child, Child, Preschool, Cytokines metabolism, Dermatitis, Atopic drug therapy, Dermatitis, Atopic physiopathology, Disease Progression, Female, Humans, Immunoglobulin E blood, Injections, Intradermal, Male, Pyroglyphidae immunology, Antigens, Bacterial administration & dosage, Dermatitis, Atopic immunology, Mycobacteriaceae immunology
- Abstract
The capacity of microbial products to inhibit allergic inflammation make them logical candidates for novel therapies in allergic diseases such as atopic dermatitis. To assess the effects of intradermal Mycobacterium vaccae derivative on allergen-specific immune responses in children with moderate to severe atopic dermatitis. Peripheral blood mononuclear cells were isolated from children aged 5-16 years who received intradermal injections of M. vaccae derivative AVAC(TM) (n = 26) or placebo (n = 34) three times at 2-weekly intervals, weeks 0, 2 and 4. Cytokine [interleukin (IL)-13, interferon (IFN)-γ and IL-10] responses to allergen [house dust mite (HDM)], mitogen [phytohaemagglutinin (PHA)], Staphylococcal enterotoxin B (SEB) and Toll-like receptor (TLR) ligands were assessed. At week 8 (1 month after all injections given) children in the AVAC group showed a significant increase in IL-10 (P = 0·009), T helper type 1 (Th1) IFN-γ (P = 0·017) and Th2 IL-13 (P = 0·004) responses to HDM compared with baseline (week 0). There were no significant changes in any cytokine production in the placebo. HDM-specific IL-10 responses remained significantly higher (P = 0·014) than at baseline in the AVAC group by week 12; however, the HDM-specific IL-13 and IFN-γ responses were no longer significantly different from baseline. IL-13 (r = 0·46, P < 0·001) and IL-10 (r = 0·27, P = 0·044) responses to HDM were correlated with total immunoglobulin E but not with disease severity. There were no effects of AVAC on mitogen, SEB, TLR-2- or TLR-4-mediated responses. This M. vaccae derivative appeared to modulate responses to HDM selectively, suggesting the capacity for in vivo effects on allergen-specific immune responses., (© 2011 Susan L Prescott. Clinical and Experimental Immunology © 2011 British Society for Immunology.)
- Published
- 2011
- Full Text
- View/download PDF
24. Ribosomal therapy in the treatment of recurrent acute adenoiditis.
- Author
-
Mora R, Dellepiane M, Crippa B, Guastini L, Santomauro V, and Salami A
- Subjects
- Acoustic Impedance Tests, Adolescent, Antigens, Bacterial adverse effects, Child, Double-Blind Method, Drug Administration Schedule, Female, Follow-Up Studies, Humans, Immunoglobulin E blood, Immunoglobulins blood, Immunologic Factors adverse effects, Male, Nasopharyngitis immunology, Pain Measurement, Rhinomanometry, Secondary Prevention, Adenoids, Antigens, Bacterial therapeutic use, Immunologic Factors therapeutic use, Nasopharyngitis drug therapy
- Abstract
The aim of this study was to evaluate the efficacy of an oral ribosomal immunotherapy in the management of children with recurrent acute adenoiditis (RAA). 60 children with RAA were included and randomly assigned into two groups (group A and B). Group A children underwent ribosomal prophylaxis, while group B received a placebo. Before, at the end and 6 months after start of the therapy, children underwent medical history, ENT examination, plasma levels of immunoglobulins class E, A, G, M (IgE, IgA, IgG, IgM), tympanometry, active anterior rhinomanometry and VAS scores by children' parents. After the treatment and at the end of the study, in the group A, the serum concentration of IgE was significantly (P < 0.05) lower than in group B (77.34 +/- 6.23 vs. 95.49 +/- 7.07 mg/dl; 74.82 +/- 6.26 vs. 94.44 +/- 7.44 mg/dl), IgA titers were significantly (P < 0.05) higher than in group B (312.04 +/- 18.41 vs. 213.20 +/- 11.82; 309.07 +/- 18.33 vs. 211.73 +/- 11.54 mg/dl) as well as serum concentration of IgG (1401.12 +/- 118.81 vs. 1101.81 +/- 109.64 mg/dl; 1412.19 +/- 116.43 vs. 1144.06 +/- 103.58 mg/dl). At the end of the study, comparison between the two groups showed, in group A: 77% of children (n = 23), versus 23% (n = 7) of group B, with a type A tympanogram; significant (P < 0.05) nasal flow decrease at the rhinomanometric measures; VAS scores were significantly (P < 0.05) improved (1.8 +/- 0.22 vs. 5.1 +/- 0.59) and frequency, severity and social impact of RAA episodes were significantly (P < 0.05) lower than group B. Our results show the therapeutic effectiveness of this approach in the prophylaxis of recurrent acute adenoiditis.
- Published
- 2010
- Full Text
- View/download PDF
25. First-in-man open clinical trial of a combined rdESAT-6 and rCFP-10 tuberculosis specific skin test reagent.
- Author
-
Bergstedt W, Tingskov PN, Thierry-Carstensen B, Hoff ST, Aggerbeck H, Thomsen VO, Andersen P, and Andersen AB
- Subjects
- Adult, Humans, Interferon-gamma metabolism, Recombinant Proteins adverse effects, Sensitivity and Specificity, Antigens, Bacterial adverse effects, Bacterial Proteins adverse effects, Tuberculin Test methods, Tuberculosis diagnosis
- Abstract
Background: Tuberculin is still the only available skin test reagent for the diagnosis of mycobacterial infection. The product has a remarkable sensitivity, but poor specificity. Previous studies, including two human phase I clinical trials, have indicated that rdESAT-6 has a potential as an improved skin test reagent. Animal studies have shown that the sensitivity may be increased by inclusion of the genetically related CFP-10 antigen in the preparation without loosing specificity., Methodology: In this study a Lactococcus fermented, recombinant skin test reagent consisting of a 1ratio1 wt/wt of rdESAT-6 and CFP-10 was manufactured according to GMP standards and tested for the first time in 42 healthy adult volunteers. The two doses of 0.01 microg or 0.1 microg were injected intradermally by the Mantoux technique with 6 or 12 weeks interval. No serious adverse events and only mild adverse reactions were reported. The reagent elicited a positive skin test reaction after the first injection in one participant, who most likely was latently infected with M. tuberculosis as indicated by an appreciable IFN gamma response just below the Quantiferon(R) cut-off level at the screening visit. None of the remaining participants in the four groups had any skin test reactions and sensitisation by the reagent could therefore be excluded., Conclusion: The investigational skin test reagent rdESAT-6 and CFP-10 appeared safe and non-sensitising in this first-in-man clinical trial in human volunteers and can now be tested in larger clinical trials involving individuals with latent M. tuberculosis infection or active TB disease., Trial Registration: ClinicalTrials.gov NCT00793702.
- Published
- 2010
- Full Text
- View/download PDF
26. Is new always better than old?: The development of human vaccines for anthrax.
- Author
-
Baillie LW
- Subjects
- Adjuvants, Immunologic, Anthrax Vaccines adverse effects, Antigens, Bacterial adverse effects, Antigens, Bacterial immunology, Bacterial Toxins adverse effects, Bacterial Toxins immunology, Clinical Trials as Topic, Humans, Injections, Recombinant Proteins adverse effects, Recombinant Proteins immunology, Anthrax prevention & control, Anthrax Vaccines immunology, Bioterrorism
- Abstract
Anthrax is caused by a Gram-positive aerobic spore-forming bacillus called Bacillus anthracis. Although primarily a disease of animals, it can also infect man, sometimes with fatal consequences. As a result of concerns over the illicit use of this organism, considerable effort is focused on the development of therapies capable of conferring protection against anthrax. while effective concerns over the toxicity of the current vaccines have driven the development of second-generation products. Recombinant Protective Antigen (rPA), the nontoxic cell-binding component of anthrax lethal toxin, is the principal immunogen of the vaccines currently undergoing human clinical trials. While these new vaccines are likely to show reduced side effects they will still require multiple needle based dosing and the inclusion of the adjuvant alum which will make them expensive to administer and stockpile. To address these issues, researchers are seeking to develop vaccine formulations capable of stimulating rapid protection following needle-free injection which are stable at room temperature to facilitate stockpiling and mass vaccination programs. Recent concerns over the potential use of molecular biology to engineer vaccine resistant strains has prompted investigators to identify additional vaccine targets with which to extend the spectrum of protection conferred by rPA. While the injection of research dollars has seen a dramatic expansion of the anthrax vaccine field it is sobering to remember that work to develop the current second generation vaccines began around the time of the first gulf war. Almost two decades and millions of dollars later we still do not have a replacement vaccine and even when we do some argue that the spectrum of protection that it confers will not be as broad as the vaccine it replaces. If we are to respond effectively to emerging biological threats we need to develop processes that generate protective vaccines in a meaningful time frame and yield products in months not decades!
- Published
- 2009
- Full Text
- View/download PDF
27. Safety and tolerability of ribosome-component immune modulator in adults and children.
- Author
-
Olivieri D, Fiocchi A, Pregliasco F, Veehof S, and Cantoni V
- Subjects
- Adult, Aged, Child, Contraindications, Drug Evaluation, Glomerulonephritis, Humans, Immune System Diseases, Product Surveillance, Postmarketing, Randomized Controlled Trials as Topic, Reproducibility of Results, Respiratory Tract Infections immunology, Respiratory Tract Infections physiopathology, Virus Diseases, Antigens, Bacterial administration & dosage, Antigens, Bacterial adverse effects, Immunologic Factors administration & dosage, Immunologic Factors adverse effects, Respiratory Tract Infections epidemiology, Respiratory Tract Infections prevention & control, Vaccination
- Abstract
Ribosomal preparations (ribosome-component immune modulators [RCIMs]) do not contain attenuated bacteria and, in contrast to live bacterial extracts, which may induce severe side effects, retain immune stimulating activity without infectious capability. This study was designed to profile the tolerability of RCIM by reviewing narratively all randomized, double-blind, placebo-controlled clinical trials and open-label studies as well as data from postmarketing surveillance studies representing >30 million prescriptions. In the various clinical trials, RCIM tolerability in terms of clinical and laboratory parameters was good. There were no significant differences between patients receiving active treatment or placebo in a survey of tolerability results from randomized, double-blind, placebo-controlled studies. Pharmacovigilance analysis does not show a change in the risk profile of RCIM. The only contraindication was correlated with known hypersensitivity to any of the product components. RCIM should not be used in case of acute streptococcal glomerulonephritis, acquired immune deficiency syndrome, severe viral disease, or severe autoimmune disease. Risk associated with the use of RCIM is negligible in recurrent upper and lower airway infections in selected populations, such as children and elderly people.
- Published
- 2009
- Full Text
- View/download PDF
28. Ribosome-component immune modulation of respiratory tract infections in children.
- Author
-
Fiocchi A, Terracciano L, Martelli A, Bernardo L, Calcinai E, and Marcassa S
- Subjects
- Antigens, Bacterial administration & dosage, Antigens, Bacterial adverse effects, Child, Child, Preschool, Clinical Trials as Topic, Drug Therapy, Humans, Immunologic Factors administration & dosage, Immunologic Factors adverse effects, Incidence, Infant, Italy, Otitis Media etiology, Otitis Media prevention & control, Respiratory Tract Infections complications, Respiratory Tract Infections immunology, Respiratory Tract Infections physiopathology, Secondary Prevention, Sinusitis etiology, Sinusitis prevention & control, Socioeconomic Factors, Treatment Outcome, Antigens, Bacterial immunology, Immunologic Factors immunology, Respiratory Tract Infections epidemiology, Respiratory Tract Infections prevention & control
- Abstract
More than 25% of infants in their first year of life and 18% of children aged between 1 and 4 years suffer from recurrent respiratory infections (RRIs) in Western countries. Although RRIs are self-limiting as a rule, complications may include otitis media, sinusitis, and bronchial and pulmonary infections. This study was designed to present the available data on immune modulators (defined as drugs that interact with the immune system and modulate immune function by stimulating a more rapid and effective immune response). A ribosome-component immune modulator (RCIM) designed to stimulate both specific and nonspecific immunity in children and thus prevent or alleviate RRI is also described. A narrative review of the literature was performed with a focus on clinical trials. Double-blind, placebo-controlled studies have shown that an RCIM effectively prevents recurrent bronchopulmonary and ear-nose-throat infections; in particular, the number, severity, and duration of infectious episodes and the numbers of antibiotic courses, concomitant medications, and days away from school (children) or the workplace (parents) were reduced. Use of a RCIM is clinically efficacious, incurs minimal risk of adverse events, and, thus, represents a consistent therapeutic approach for RRIs.
- Published
- 2009
- Full Text
- View/download PDF
29. Paradoxical reaction in tubercular meningitis resulting in involvement of optic radiation.
- Author
-
Monga PK and Dhaliwal U
- Subjects
- Adult, Allergens adverse effects, Antitubercular Agents therapeutic use, Blindness etiology, Cerebral Infarction diagnostic imaging, Cerebral Infarction etiology, Drug Therapy, Combination, Female, Glucocorticoids therapeutic use, Humans, Optic Neuritis diagnosis, Optic Neuritis drug therapy, Parietal Lobe diagnostic imaging, Parietal Lobe pathology, Pupil Disorders etiology, Tomography, X-Ray Computed, Tuberculosis, Meningeal diagnosis, Tuberculosis, Meningeal drug therapy, Visual Fields, Antigens, Bacterial adverse effects, Mycobacterium tuberculosis immunology, Optic Neuritis etiology, Tuberculosis, Meningeal complications
- Abstract
A 25-year-old woman was diagnosed to have tubercular meningitis (TBM) with a right parietal infarct. She responded well to four-drug anti-tubercular treatment (ATT), systemic steroids and pyridoxine. Steroids were tapered off in one and a half months; she was put on two-drug ATT after two months. Six months after initial diagnosis she presented with sudden, bilateral visual loss. Vision was 3/200 with afferent pupillary defect and un-recordable field in the right eye; vision was 20/60 in the left eye, pupillary reaction was sluggish and the field showed a temporal hemianopia. On reintroduction of systemic corticosteroids vision improved (20/120 in right eye and 20/30 in left eye) within three days; the field defects improved sequentially to a left homonymous hemianopia, then a left homonymous inferior quadrantonopia. A diagnosis of TBM, on treatment, with bilateral optic neuritis, and right optic radiation involvement was made. Since the patient had been off ethambutol for four months, the optic neuritis and optic radiation lesion were attributed to a paradoxical reaction to tubercular allergen, corroborated by prompt recovery in response to corticosteroids. This is the first report of optic radiation involvement in a paradoxical reaction in neuro-tuberculosis in a young adult.
- Published
- 2009
- Full Text
- View/download PDF
30. Risk of sensitization in healthy adults following repeated administration of rdESAT-6 skin test reagent by the Mantoux injection technique.
- Author
-
Lillebaek T, Bergstedt W, Tingskov PN, Thierry-Carstensen B, Aggerbeck H, Hoff ST, Weldingh K, Andersen P, Soborg B, Thomsen VO, and Andersen AB
- Subjects
- Adolescent, Adult, Antigens, Bacterial administration & dosage, Antigens, Bacterial immunology, Bacterial Proteins administration & dosage, Bacterial Proteins immunology, Female, Humans, Hypersensitivity, Delayed etiology, Hypersensitivity, Delayed immunology, Injections, Intradermal, Interferon-gamma biosynthesis, Intradermal Tests methods, Male, Middle Aged, Young Adult, Antigens, Bacterial adverse effects, Bacterial Proteins adverse effects, Intradermal Tests adverse effects, Tuberculosis diagnosis
- Abstract
Limited specificity of the tuberculin skin test incited the development of the intradermal Mycobacterium tuberculosis-specific rdESAT-6 skin test. Animal studies have shown, however, that there is a possible risk of sensitization when repeated injections of rdESAT-6 are given. The aim of this phase 1 open clinical trial was to assess the sensitization risk and safety of repeated administration of rdESAT-6 reagent in 31 healthy adult volunteers. Three groups of volunteers received two fixed doses of 0.1 microg rdESAT-6 28, 56 or 112 days apart, respectively. After the second injection, the diameter of induration and/or redness at the injection site was measured and taken as a possible sensitization reaction if >5mm. In vitro interferon gamma (IFN-gamma) responses were measured as supportive evidence. Local adverse reactions at the injection site and adverse events were recorded. One out of 31 (3%) volunteers showed a positive skin reaction (sensitization) upon a second injection of rdESAT-6 after 28days and an increased IFN-gamma response to ESAT-6. For 7 (23%) of the volunteers, local adverse reactions related to the product were registered, but all reactions were mild and predictable. In conclusion, repeated injections of the rdESAT-6 skin test reagent are safe, and sensitization occurs at a low rate, especially if the time span between succeeding doses is wide.
- Published
- 2009
- Full Text
- View/download PDF
31. Double-blind randomized Phase I study comparing rdESAT-6 to tuberculin as skin test reagent in the diagnosis of tuberculosis infection.
- Author
-
Arend SM, Franken WP, Aggerbeck H, Prins C, van Dissel JT, Thierry-Carstensen B, Tingskov PN, Weldingh K, and Andersen P
- Subjects
- Adult, Aged, Dose-Response Relationship, Drug, Double-Blind Method, Humans, Middle Aged, Mycobacterium tuberculosis immunology, Observer Variation, Skin Tests adverse effects, Tuberculin Test adverse effects, Tuberculin Test methods, Antigens, Bacterial administration & dosage, Antigens, Bacterial adverse effects, Bacterial Proteins administration & dosage, Bacterial Proteins adverse effects, Skin Tests methods, Tuberculosis diagnosis
- Abstract
Limited specificity of the tuberculin skin test incited the development of in vitro assays based on Mycobacterium tuberculosis-specific antigens such as ESAT-6 that are lacking in Bacillus Calmette Guérin (BCG). In animal studies, intradermal ESAT-6 was safe and induced specific skin test responses. The aim of the study was to assess the safety of intradermal recombinant dimer ESAT-6 (rdESAT-6) compared with tuberculin and to determine the human dose. The study design was a double-blind Phase I study with intra-subject randomization to the left and right forearm, comparing 2 Tuberculin Units (TU) intradermal tuberculin (RT23) with 0.01, 0.1, 1 or 10 microg rdESAT-6 in groups of five healthy controls or treated tuberculosis (TB) patients. The risk of sensitization after skin testing was assessed in healthy volunteers. All doses were tolerated well by healthy volunteers and responses to rdESAT-6 were limited to transient redness after 24 h only at the highest dose. No sensitization was observed. Because 1 microg rdESAT-6 induced large responses with local side effects in some TB patients, the 10 microg dose of rdESAT-6 was not tested. Mean responses to 0.01, 0.1 and 1 microg rdESAT-6 measured 14.0, 19.8 and 38.8 mm of redness, respectively, and 7.0, 13.4 and 14.6 mm of induration. The response to tuberculin was similar to the responses to 0.1 microg rdESAT-6. Mild local side effects due to tuberculin and rdESAT-6 were observed in 8/15, respectively, 6/15 patients, more pronounced at the highest rdESAT-6 dose. In conclusion, this pilot Phase I study of safety, feasibility and dose finding of intradermal rdESAT-6 provides proof of principle of a specific skin test for human use. No serious adverse events were observed but the study was not sufficiently powered to demonstrate complete safety. Intradermal rdESAT-6 did not seem to sensitize healthy volunteers. In treated TB patients, responses to rdESAT-6 were optimal at 0.1 microg. Further studies are needed to evaluate sensitization after repeated doses and to study the effect of additional CFP-10 on the sensitivity of a TB-specific skin test.
- Published
- 2008
- Full Text
- View/download PDF
32. Immunogenicity and reactogenicity of acellular pertussis booster vaccines in children: standard pediatric versus a reduced-antigen content formulation.
- Author
-
Meyer CU, Habermehl P, Knuf M, Hoet B, Wolter J, and Zepp F
- Subjects
- Antibodies, Bacterial blood, Antigens, Bacterial adverse effects, Antigens, Bacterial immunology, Child, Child, Preschool, Diphtheria immunology, Diphtheria prevention & control, Female, Germany, Humans, Male, Tetanus immunology, Tetanus prevention & control, Vaccines, Acellular adverse effects, Vaccines, Acellular immunology, Immunization, Secondary methods, Pertussis Vaccine adverse effects, Pertussis Vaccine immunology, Whooping Cough immunology, Whooping Cough prevention & control
- Abstract
Booster vaccination with a reduced-antigen-content dTpa, pediatric DTPa or adult Td vaccine in DTPa-primed children aged 4-6 years was evaluated. Immunogenicity and CMI was assessed one month and 3.5 years after vaccination. Symptoms were solicited for 15 days post-vaccination. There were no differences between groups in diphtheria or tetanus seroprotection or pertussis vaccine-response rates. Anti-diphtheria and anti-PRN concentrations were higher after DTPa, but groups differences reduced over time. Non-significant trends toward reduced reactogenicity of dTpa were observed. Many factors influence vaccine choice at preschool age. The dTpa vaccine was as immunogenic and possibly better tolerated than DTPa at this age.
- Published
- 2008
- Full Text
- View/download PDF
33. [Assessment of immunity and allergy after vaccination with dry combined anthrax vaccine].
- Author
-
Shevtsov AN, Darmov IV, Saîtseva GA, Borovskoî DV, Menovshchikov VA, Kunof VK, and Gracheva TA
- Subjects
- Adult, Animals, Anthrax blood, Anthrax prevention & control, Anthrax Vaccines administration & dosage, Antibodies, Bacterial blood, Antigens, Bacterial adverse effects, Blood Group Antigens blood, Female, Humans, Immunization, Passive, Injections, Subcutaneous, Male, Mice, Rh-Hr Blood-Group System blood, Time Factors, Vaccines, Combined administration & dosage, Vaccines, Combined adverse effects, Vaccines, Combined immunology, Anthrax immunology, Anthrax Vaccines adverse effects, Anthrax Vaccines immunology, Antigens, Bacterial immunology, Bacillus anthracis immunology, Hypersensitivity etiology, Immune Sera immunology
- Abstract
Study of humoral immune response and allergy in recipients of dry combined anthrax vaccine was performed. Immune response was assessed by antibody titers to protective antigen and by index of preventive properties of blood serum (PPS) of recipients. Relation of index of PPS and antibody titers in blood serum of the donors was established. Distribution of erythrocyte antigens in recipients of live dry and combined anthraxvaccines depending on blood group, Rh-factor, and age was studied. It has been shown that 80% of recipients of dry combined anthrax vaccine formed potent immunity with its high level lasted for 8 months. Study of allergenic properties of the combined anthrax vaccine using registration of neutrophils chemiluminescence in vivo showed low level of sensitization of vacinees.
- Published
- 2007
34. Comparative in silico analysis of two vaccine candidates for group A streptococcus predicts that they both may have similar safety profiles.
- Author
-
Shaila MS, Nayak R, Prakash SS, Georgousakis M, Brandt E, McMillan DJ, Batzloff MR, Pruksakorn S, Good MF, and Sriprakash KS
- Subjects
- Amino Acid Sequence, Antibodies, Bacterial blood, Antibodies, Bacterial immunology, Antigens, Bacterial adverse effects, Antigens, Bacterial genetics, Antigens, Bacterial immunology, Bacterial Outer Membrane Proteins adverse effects, Bacterial Outer Membrane Proteins genetics, Bacterial Outer Membrane Proteins immunology, Basic-Leucine Zipper Transcription Factors, Blood Donors, Carrier Proteins adverse effects, Carrier Proteins genetics, Carrier Proteins immunology, Computational Biology, Cross Reactions, DNA-Binding Proteins genetics, DNA-Binding Proteins metabolism, Epitopes, Histocompatibility Antigens Class I metabolism, Histocompatibility Antigens Class II metabolism, Humans, Recombinant Fusion Proteins genetics, Recombinant Fusion Proteins metabolism, Saccharomyces cerevisiae Proteins genetics, Saccharomyces cerevisiae Proteins metabolism, Streptococcus pyogenes genetics, Streptococcus pyogenes metabolism, Transcription Factors genetics, Transcription Factors metabolism, Antigens, Bacterial chemistry, Bacterial Outer Membrane Proteins chemistry, CD4-Positive T-Lymphocytes immunology, Carrier Proteins chemistry, Lymphocyte Activation immunology, Peptides chemistry, Recombinant Fusion Proteins immunology, Streptococcal Vaccines adverse effects, Streptococcus pyogenes immunology
- Abstract
Background: Concerns of immune cross-reactivity, between epitopes of the group A streptococcal (GAS) M-proteins and host proteins have hindered the progress of an effective GAS vaccine. An ideal M-protein based subunit vaccine should not elicit heart tissue cross-reactive antibody responses and should not activate M-protein specific CD4+ T-cells. In the current study we used a bioinformatic and immunoinformatic approach to assess the safety of J8 and J14, chimeric vaccine constructs containing a GAS derived M-protein epitope embedded in flanking GCN4 region. We demonstrate that at the primary amino acid level J8 and J14 show very little homology to human proteins. ProPred, RANKPEP and HLABIND algorithms failed to predict significant binding between the M-protein specific regions of J8 and J14 and class II binding alleles. A single peptide was predicted to bind to HLA class I allele B_2705. This data was supported by cellular proliferation assays demonstrating few peripheral blood mononuclear cells (PBMCs) from donors respond to J8 and J14. Reassuringly, there was no correlation between proliferation to these peptides, and proliferation to host proteins. This data suggests that J8 and J14 are unlikely to induce cross-reactive immune responses, and will be safe for use in humans.
- Published
- 2007
- Full Text
- View/download PDF
35. Systemic anthrax lethal toxin therapy produces regressions of subcutaneous human melanoma tumors in athymic nude mice.
- Author
-
Abi-Habib RJ, Singh R, Leppla SH, Greene JJ, Ding Y, Berghuis B, Duesbery NS, and Frankel AE
- Subjects
- Animals, Antigens, Bacterial administration & dosage, Antigens, Bacterial adverse effects, Bacterial Toxins administration & dosage, Bacterial Toxins adverse effects, Dose-Response Relationship, Drug, Drug Administration Schedule, Female, Humans, Injections, Subcutaneous, Melanoma pathology, Mice, Mice, Nude, Skin Neoplasms pathology, Treatment Outcome, Tumor Burden, Xenograft Model Antitumor Assays methods, Antigens, Bacterial therapeutic use, Bacterial Toxins therapeutic use, Melanoma drug therapy, Skin Neoplasms drug therapy
- Abstract
Purpose: Anthrax Lethal Toxin (LeTx), composed of protective antigen and lethal factor, catalytically cleaves mitogen-activated protein kinase (MAPK) kinases and inhibits the MAPK signaling pathways. The majority of metastatic melanomas possess the V599E BRAF mutation, which constitutively activates MAPK1/2 signaling. LeTx is cytotoxic to BRAF mutant melanoma cell lines in vitro, whereas most normal cells are resistant to this toxin. In this study, we determine the in vivo potency and safety of systemically administered LeTx., Experimental Design: A s.c. xenograft melanoma model in athymic nude mice was treated with different i.p. doses of LeTx., Results: In this study, we show that in vivo systemic LeTx treatment of s.c. xenograft melanoma tumors in athymic nude mice yields partial and complete tumor regressions with minor toxicity to mice. When animal toxicity was observed, we did not find any histologic evidence of tissue damage., Conclusions: LeTx is one of the rare targeted agents to produce complete remissions of human melanomas in an animal model and thus warrants further preclinical development.
- Published
- 2006
- Full Text
- View/download PDF
36. Introducing Vi polysaccharide typhoid fever vaccine to primary school children in North Jakarta, Indonesia, via an existent school-based vaccination platform.
- Author
-
Agtini MD, Ochiai RL, Soeharno R, Lee HJ, Sundoro J, Hadinegoro SR, Han OP, Tana L, Halim FX, Ghani L, Delima, Lestari W, Sintawati FX, Kusumawardani N, Malik R, Santoso TS, Nadjib M, Soeroso S, Wangsasaputra F, Ali M, Ivanoff B, Galindo CM, Pang T, Clemens JD, Suwandono A, and Acosta CJ
- Subjects
- Antigens, Bacterial adverse effects, Child, Feasibility Studies, Humans, Indonesia, Pilot Projects, Polysaccharides, Bacterial adverse effects, Program Evaluation, Refrigeration, Safety, Students, Typhoid-Paratyphoid Vaccines adverse effects, Typhoid-Paratyphoid Vaccines supply & distribution, Antigens, Bacterial administration & dosage, Mass Vaccination organization & administration, Polysaccharides, Bacterial administration & dosage, Salmonella enterica immunology, School Health Services organization & administration, Typhoid Fever prevention & control, Typhoid-Paratyphoid Vaccines administration & dosage
- Abstract
Objectives: To report results on coverage, safety and logistics of a large-scale, school-based Vi polysaccharide immunization campaign in North Jakarta., Methods: Of 443 primary schools in North Jakarta, Indonesia, 18 public schools were randomly selected for this study. Exclusion criteria were fever 37.5 degrees C or higher at the time of vaccination or a known history of hypersensitivity to any vaccine. Adverse events were monitored and recorded for 1 month after immunization. Because this was a pilot programme, resource use was tracked in detail., Results: During the February 2004 vaccination campaign, 4828 students were immunized (91% of the target population); another 394 students (7%) were vaccinated during mop-up programmes. Informed consent was obtained for 98% of the target population. In all, 34 adverse events were reported, corresponding to seven events per 1000 doses injected; none was serious. The manufacturer recommended cold chain was maintained throughout the programme., Conclusions: This demonstration project in two sub-districts of North Jakarta shows that a large-scale, school-based typhoid fever Vi polysaccharide vaccination campaign is logistically feasible, safe and minimally disruptive to regular school activities, when used in the context of an existing successful immunization platform. The project had high parental acceptance. Nonetheless, policy-relevant questions still need to be answered before implementing a widespread Vi polysaccharide vaccine programme in Indonesia.
- Published
- 2006
- Full Text
- View/download PDF
37. Safety of reduced-antigen-content tetanus-diphtheria-acellular pertussis vaccine in adolescents as a sixth consecutive dose of acellular pertussis-containing vaccine.
- Author
-
Zepp F, Knuf M, Habermehl P, Mannhardt-Laakmann W, Howe B, and Friedland LR
- Subjects
- Adolescent, Child, Cross-Over Studies, Diphtheria prevention & control, Dose-Response Relationship, Drug, Double-Blind Method, Female, Follow-Up Studies, Germany epidemiology, Humans, Immunization Schedule, Incidence, Male, Prospective Studies, Severity of Illness Index, Tetanus prevention & control, Treatment Outcome, Vaccination adverse effects, Whooping Cough prevention & control, Antigens, Bacterial administration & dosage, Antigens, Bacterial adverse effects, Diphtheria-Tetanus-acellular Pertussis Vaccines administration & dosage, Diphtheria-Tetanus-acellular Pertussis Vaccines adverse effects
- Abstract
Objective: The safety of a booster dose of a reduced-antigen-content tetanus-diphtheria-acellular pertussis (Tdap) vaccine was evaluated in adolescents previously vaccinated with five doses of acellular pertussis-containing vaccine., Study Design: Adolescents (n = 319) previously vaccinated with either 5 doses of diphtheria-tetanus-acellular pertussis (DTaP) (n = 193) or 4 doses of DTaP plus another acellular pertussis-containing vaccine received one dose each of Tdap and hepatitis A vaccine in a double-blinded, randomized, crossover trial. Rates of adverse events (AEs) after vaccination with Tdap versus hepatitis A and rates of local AEs among adolescents vaccinated with Tdap (sixth acellular pertussis-containing vaccine dose) versus rates in these same individuals after vaccination with their fifth DTaP dose were assessed., Results: After Tdap, pain (63.6%), redness (51.7%), and swelling (41.4%) were the most frequently reported AEs. Large injection site swelling (swelling > 100 mm, arm circumference increase > 50 mm or diffuse swelling interfering with daily activities) occurred in three adolescents and resolved without sequelae. After the sixth dose of acellular pertussis-containing vaccine, adolescents reported more pain and less redness and swelling compared with incidences of these AEs reported when these same individuals received their fifth DTaP dose., Conclusions: These results suggest that Tdap is well tolerated as a sixth consecutive dose of acellular pertussis-containing vaccine.
- Published
- 2006
- Full Text
- View/download PDF
38. Recommendation for an adolescent dose of tetanus and diphtheria toxoids and acellular pertussis vaccine: reassurance for the future.
- Author
-
Halperin SA
- Subjects
- Adolescent, Child, Diphtheria prevention & control, Dose-Response Relationship, Drug, Humans, Immunization Schedule, Tetanus prevention & control, Vaccination adverse effects, Vaccination trends, Whooping Cough prevention & control, Antigens, Bacterial administration & dosage, Antigens, Bacterial adverse effects, Diphtheria-Tetanus-acellular Pertussis Vaccines administration & dosage, Diphtheria-Tetanus-acellular Pertussis Vaccines adverse effects, Health Planning Guidelines
- Published
- 2006
- Full Text
- View/download PDF
39. Immunogenicity and tolerance of ascending doses of a recombinant protective antigen (rPA102) anthrax vaccine: a randomized, double-blinded, controlled, multicenter trial.
- Author
-
Gorse GJ, Keitel W, Keyserling H, Taylor DN, Lock M, Alves K, Kenner J, Deans L, and Gurwith M
- Subjects
- Adjuvants, Immunologic administration & dosage, Adolescent, Adult, Aluminum Hydroxide administration & dosage, Aluminum Hydroxide immunology, Anthrax Vaccines administration & dosage, Anthrax Vaccines genetics, Antibodies, Bacterial blood, Antigens, Bacterial administration & dosage, Antigens, Bacterial genetics, Bacterial Toxins administration & dosage, Bacterial Toxins genetics, Dose-Response Relationship, Immunologic, Double-Blind Method, Enzyme-Linked Immunosorbent Assay, Female, Humans, Immunization Schedule, Injections, Intramuscular, Male, Neutralization Tests, Vaccines, Synthetic administration & dosage, Vaccines, Synthetic adverse effects, Vaccines, Synthetic genetics, Vaccines, Synthetic immunology, Anthrax Vaccines adverse effects, Anthrax Vaccines immunology, Antigens, Bacterial adverse effects, Antigens, Bacterial immunology, Bacterial Toxins adverse effects, Bacterial Toxins immunology
- Abstract
Background: We report the results of a phase I dose escalation, safety and immunogenicity trial of a new recombinant protective antigen (rPA102) anthrax vaccine., Methods: Hundred healthy volunteers were randomized in a 4:1 ratio to receive intramuscular doses of rPA102 in the following formulations: 5, 25, 50, or 75 microg of rPA102 in 82.5 microg aluminum hydroxide adjuvant at 0, 4, and 8 weeks; or the US licensed Anthrax Vaccine Adsorbed (AVA) at weeks 0 and 4., Findings: Local reactogenicity (mostly pain) was more common with AVA than with rPA102 following the first (94.7% versus 44.4%; p < 0.001) and the second (84.2% versus 35.4%; p < 0.001) vaccinations. Systemic reactogenicity (mostly headache) was more common among rPA102 vaccinees, but only following the first vaccination (49.4% versus 15.8%; p = 0.025). A dose-response relationship for anti-PA antibodies was present after the 2nd and 3rd vaccinations. Two weeks following the 2nd vaccination, the geometric mean titers (GMT) for lethal toxin neutralization activity (TNA), for the 5, 25, 50 and 75 microg rPA102 and AVA groups were 38.6, 75.4, 373.9, 515.3, and 855.2, respectively. The geometric mean concentrations (GMC) measured by anti-PA IgG ELISA were 3.7, 11.5, 25.9, 44.1, and 171.6, respectively. Two weeks following the 3rd vaccination, TNA GMTs for the four rPA102 groups, were: 134.7, 719.7, 2116.6, 2422.4; and ELISA GMCs were: 22.9, 104.7, 196.4, and 262.6, respectively., Interpretation: No clinically serious or dose-related toxicity or reactogenicity was observed. The TNA response after two injections of the 75 microg dose of rPA102 was similar to the response after two injections of AVA. The third rPA102 vaccination substantially increased the antibody response.
- Published
- 2006
- Full Text
- View/download PDF
40. Assessment of nine candidate DTP-vaccines with reduced amount of antigen and/or without adjuvant as a fourth (booster-) dose in the second year of life.
- Author
-
Knuf M, Habermehl P, Faber J, Bock HL, Sänger R, Bogaerts H, Clemens R, Schuind A, du Prel JB, and Schmitt HJ
- Subjects
- Adjuvants, Immunologic adverse effects, Antigens, Bacterial adverse effects, Antigens, Bacterial immunology, Child, Preschool, Diphtheria-Tetanus-acellular Pertussis Vaccines immunology, Dose-Response Relationship, Immunologic, Double-Blind Method, Female, Humans, Immunization, Secondary adverse effects, Infant, Male, Adjuvants, Immunologic administration & dosage, Antigens, Bacterial administration & dosage, Diphtheria-Tetanus-acellular Pertussis Vaccines administration & dosage, Diphtheria-Tetanus-acellular Pertussis Vaccines adverse effects, Immunization, Secondary methods
- Abstract
Background: The incidence of local reactions to diphtheria-, tetanus and acellular pertussis (DTaP-) vaccines in infants and toddlers increases with each subsequent dose, and entire thigh swellings (ETS) have been reported. Lowering the amount of antigen or of adjuvant may decrease the reactogenicity of DTaP while maintaining a protective immune response., Objectives: Following priming with three doses of a DTaP vaccine during infancy, the safety, reactogenicity and immunogenicity of nine different candidate DTaP-vaccines with reduced amounts of antigen and/or adjuvant given as fourth (booster) dose were evaluated., Methods: Study participants were healthy infants aged 15-27 months at the time of booster vaccination. Each participant had received three doses of a DTaP vaccine (Infanrixtrade mark, GlaxoSmithKline, Rixensart, Belgium; "reference DTaP") at age 3, 4, and 5 months as part of a previous clinical trial. More than 20,000 children were eligible for participation in the current study protocol at the time. In a first phase at a University hospital-based vaccination study center, nine sequential cohorts of 63-119 study subjects received one of nine different candidate vaccines. Patients and study personal were blinded with regard to which vaccine was currently in use. Reactogenicity was solicited from parents using diary cards. Blood was drawn prior to and 4 weeks after vaccination and immediately centrifuged. The serum was stored at -20 degrees C until serology was performed by ELISA tests. As soon as the first candidate vaccine with adequate reactogenicity and immunogenicity profile was identified in the first study phase, a second study phase was initiated in parallel, to evaluate the safety and reactogenicity of the respective candidate vaccine in private practices in large cohorts (1613-2095 study subjects per group)., Results: In the first study phase, DTaP with no aluminum induced the highest frequency of ETS and fever. All other candidate vaccines caused lower rates of local and general reactions than the reference DTaP. As a general rule, vaccines with less antigen induced fewer reactions, although there was no strict dose-response effect and the difference, e.g. between a one-tenth and a one-fifth DTaP dose (DTaP 1/5; DTaP 1/10) was not clinically relevant. Separate injections of Td and aP caused fewer general reactions than the respective TdaP combination and local reactions were higher at the aP than at the Td injection site. Again, as a general rule, reduced amounts of antigen induced lower antibody concentrations, although all vaccines induced "protective" anti-tetanus and anti-diphtheria antibody responses. A total of 92-100% of children showed seroresponses to pertussis antigens even when vaccinated with reduced amounts of the respective pertussis antigen. Elimination of aluminum from DTaP vaccine induced higher anti-tetanus-antibody concentrations and so did a reduction of the amount of diphtheria antigen. Additional examples for antigen interaction were increased antibody concentrations, observed with injection of Td and aP into different limbs. In the second study phase, all three vaccines evaluated (one with a reduced amount of diphtheria antigen, TdaP; one with reduced amounts of all antigens, tdap; and one with a fifth dose of the reference vaccine (DTaP 1/5)) were safe and had an acceptable reactogenicity profile in a total of 4871 study subjects., Conclusions: Local reactions due to DTaP booster doses in the second year of life can be reduced by reducing the amount of antigen in the respective vaccine while an adequate immunogenicity is maintained. Aluminum-free vaccines induced ETS and fever most commonly. Any changes in vaccine composition should lead to a full evaluation of the new product.
- Published
- 2006
- Full Text
- View/download PDF
41. The New World primate, Aotus nancymae, as a model for examining the immunogenicity of a prototype enterotoxigenic Escherichia coli subunit vaccine.
- Author
-
Jones FR, Hall ER, Tribble D, Savarino SJ, Cassels FJ, Porter C, Meza R, Nunez G, Espinoza N, Salazar M, Luckett R, and Scott D
- Subjects
- Adjuvants, Immunologic, Administration, Intranasal, Animals, Antigens, Bacterial administration & dosage, Antigens, Bacterial adverse effects, Antigens, Bacterial immunology, Bacterial Toxins administration & dosage, Bacterial Toxins genetics, Bacterial Toxins immunology, Blood Cell Count, Blood Chemical Analysis, Enterotoxins administration & dosage, Enterotoxins genetics, Enterotoxins immunology, Escherichia coli Infections prevention & control, Escherichia coli Proteins administration & dosage, Escherichia coli Proteins adverse effects, Escherichia coli Proteins genetics, Escherichia coli Proteins immunology, Escherichia coli Vaccines administration & dosage, Escherichia coli Vaccines adverse effects, Female, Gastric Lavage, Immunoglobulin A blood, Immunoglobulin G blood, Lactic Acid, Male, Mutation, Polyglycolic Acid, Polylactic Acid-Polyglycolic Acid Copolymer, Polymers, Vaccines, Subunit administration & dosage, Vaccines, Subunit adverse effects, Antibodies, Bacterial blood, Aotidae, Escherichia coli immunology, Escherichia coli Vaccines immunology, Models, Animal, Vaccines, Subunit immunology
- Abstract
The colonization factors (CF) of enterotoxigenic Escherichia coli (ETEC) are being targeted for inclusion in a multi-subunit ETEC vaccine. This study was designed to examine the preclinical safety and immunogenicity of CF CS6, encapsulated in a biodegradable poly(DL-lactide-co-glycolide) (meCS6), and administered in the presence or absence of a mutated heat-labile enterotoxin, LT(R192G), in the non-human primate, Aotus nancymae. A. nancymae were inoculated intranasally (IN) with meCS6 (200 microg; positive control), or intragastrically (IG) with meCS6 (200 or 1000 microg) with or without 2 microg LT(R192G) in three doses given at 2-week intervals. In a second experiment, A. nancymae were inoculated IG with 950 microg of meCS6 with or without 2 microg LT(R192G) in four doses given every 48 h. Blood was collected to assess anti-CS6 and -LT serum immunoglobulin G (IgG) and IgA responses and safety variables (complete blood count and chemistry). Safety parameters were unchanged from baseline following all vaccinations. In Experiment 1, a dose-related serologic response to CS6 was observed; 78.6 and 57.1% of monkeys given 1000 microg meCS6 (n = 14) had a serum IgG and IgA response, respectively, compared to only 28.6% of monkeys given 200 microg meCS6 (n = 14) with a serum IgG and IgA response. No significant effect on the number of responders or the magnitude of responses was observed with the addition of LT(R192G). The three-dose, 2-week regimen with 1000 microg meCS6 was more effective at eliciting an immune response than the four-dose, 48-h regimen with 950 microg meCS6. Results from this study indicate that A. nancymae provide a useful ETEC preclinical safety and immunogenicity model.
- Published
- 2006
- Full Text
- View/download PDF
42. The contribution of Aeromonas salmonicida extracellular products to the induction of inflammation in Atlantic salmon (Salmo salar L.) following vaccination with oil-based vaccines.
- Author
-
Mutoloki S, Brudeseth B, Reite OB, and Evensen O
- Subjects
- Animals, Fish Diseases microbiology, Histological Techniques veterinary, Inflammation etiology, Inflammation pathology, Leukocyte Count veterinary, Vaccination adverse effects, Aeromonas salmonicida immunology, Antigens, Bacterial adverse effects, Fish Diseases etiology, Fish Diseases pathology, Inflammation veterinary, Salmo salar, Vaccination veterinary
- Abstract
Intraperitoneal injection of Atlantic salmon with oil-based vaccines often results in severe side effects. Aeromonas salmonicida subspecies salmonicida, a primary antigen in the vaccines, produces extracellular products (ECPs) that are included in the formulation but the role of ECPs in inducing side effects is not well understood. In the present study, we evaluated the contribution of ECPs to early inflammatory reactions since early events determine the outcome of inflammation. Five groups of Atlantic salmon pre-smolts were injected intraperitoneally with one of the following preparations: (1) A. salmonicida water-in-oil (w/o) containing standard amounts of ECPs; (2) A. salmonicida (w/o) with ECPs concentrated five times; (3) A. salmonicida (w/o) without ECPs (ECPs were removed by washing and re-suspension of the bacteria prior to formulation); (4) w/o only (without antigens), and (5) physiological saline. Tissue sections of the injection site (pyloric caeca and surrounding areas) were collected at monthly intervals for 4 months in phosphate buffered formalin and processed for light microscopy. Computer-assisted microscopy with the help of Image Pro analysis program was used to measure the area of inflammation on H&E stained sections. Differential cell counts of leucocytes involved in the inflammatory reaction were also done based on morphology. Overall results show that fish injected with vaccines containing concentrated amounts of ECPs displayed a higher average area of inflammation compared to all other groups. In contrast, washed preparations induced mild reactions compared to vaccines containing either standard or concentrated ECPs. Mild, non-persistent reactions were observed in the group injected with oil adjuvant only. Neutrophils were persistent in inflammations induced by all preparations except w/o only. No inflammatory reactions were observed in the group injected with PBS. The results suggest that ECPs are pro-inflammatory in Atlantic salmon. It is anticipated that ECPs are more readily exposed to inflammatory cells than the bacterial cells themselves during early stages of inflammation because of their orientation at the water-oil interface. The results indicate that ECPs of A. salmonicida play an important role in the induction of early inflammatory reactions. It is also documented that the combination of antigens with oil adjuvants, and not the adjuvants alone, is the inducer of strong inflammatory reactions in Atlantic salmon.
- Published
- 2006
- Full Text
- View/download PDF
43. Revocation of status of specific products; Group A streptococcus. Direct final rule.
- Subjects
- Antigens, Bacterial adverse effects, Antigens, Bacterial therapeutic use, Biological Products classification, Humans, Streptococcal Infections prevention & control, Streptococcal Vaccines therapeutic use, United States, United States Food and Drug Administration, Vaccines, Inactivated therapeutic use, Streptococcus pyogenes classification
- Abstract
The Food and Drug Administration (FDA) is removing the regulation applicable to the status of specific products; Group A streptococcus. FDA is removing the regulation because the existing requirement for Group A streptococcus organisms and derivatives is both obsolete and a perceived impediment to the development of Group A streptococcus vaccines. The regulation was written to apply to a group of products that are no longer on the market. We are taking this action as part of our continuing effort to reduce the burden of unnecessary regulations on industry and to revise outdated regulations without diminishing public health protection. We are issuing the removal directly as a final rule because it is noncontroversial, and there is little likelihood that we will receive any significant adverse comments. Elsewhere in this issue of the Federal Register, we are publishing a companion proposed rule under our usual procedures for notice and comment in the event that we receive any significant adverse comments on the direct final rule. If we receive any significant adverse comments that warrant terminating the direct final rule, we will consider such comments on the proposed rule in developing the final rule.
- Published
- 2005
44. A mass vaccination campaign targeting adults and children to prevent typhoid fever in Hechi; expanding the use of Vi polysaccharide vaccine in southeast China: a cluster-randomized trial.
- Author
-
Yang J, Acosta CJ, Si GA, Zeng J, Li CY, Liang DB, Ochiai RL, Page AL, Danovaro-Holliday MC, Zhang J, Zhou BD, Liao HZ, Wang ML, Tan DM, Tang ZZ, Gong J, Park JK, Ali M, Ivanoff B, Liang GC, Yang HH, Pang T, Xu ZY, Donner A, Galindo CM, Dong BQ, and Clemens JD
- Subjects
- Adolescent, Adult, Antigens, Bacterial adverse effects, Child, China epidemiology, Cluster Analysis, Feasibility Studies, Geography, Humans, Injections, Intramuscular, Injections, Subcutaneous, Meningitis, Meningococcal prevention & control, Meningococcal Vaccines administration & dosage, Meningococcal Vaccines adverse effects, Middle Aged, Polysaccharides, Bacterial adverse effects, Public Health Administration, Safety, Social Marketing, Typhoid Fever epidemiology, Typhoid-Paratyphoid Vaccines adverse effects, Antigens, Bacterial administration & dosage, Mass Vaccination organization & administration, Polysaccharides, Bacterial administration & dosage, Typhoid Fever prevention & control, Typhoid-Paratyphoid Vaccines administration & dosage
- Abstract
Background: One of the goals of this study was to learn the coverage, safety and logistics of a mass vaccination campaign against typhoid fever in children and adults using locally produced typhoid Vi polysaccharide (PS) and group A meningococcal PS vaccines in southern China., Methods: The vaccination campaign targeted 118,588 persons in Hechi, Guangxi Province, aged between 5 to 60 years, in 2003. The study area was divided into 107 geographic clusters, which were randomly allocated to receive one of the single-dose parenteral vaccines. All aspects regarding vaccination logistics, feasibility and safety were documented and systematically recorded. Results of the logistics, feasibility and safety are reported., Results: The campaign lasted 5 weeks and the overall vaccination coverage was 78%. On average, the 30 vaccine teams gave immunizations on 23 days. Vaccine rates were higher in those aged < or = 15 years (90%) than in adolescents and young adults (70%). Planned mop-up activities increased the coverage by 17%. The overall vaccine wastage was 11%. The cold chain was maintained and documented. 66 individuals reported of adverse events out of all vaccinees, where fever (21%), malaise (19%) and local redness (19%) were the major symptoms; no life-threatening event occurred. Three needle-sharp events were reported., Conclusion: The mass immunization proved feasible and safe, and vaccine coverage was high. Emphasis should be placed on: injection safety measures, community involvement and incorporation of mop-up strategies into any vaccination campaign. School-based and all-age Vi mass immunizations programs are potentially important public health strategies for prevention of typhoid fever in high-risk populations in southern China.
- Published
- 2005
- Full Text
- View/download PDF
45. Immune responses to an oral typhoid vaccine strain that is modified to constitutively express Vi capsular polysaccharide.
- Author
-
Tacket CO, Pasetti MF, Sztein MB, Livio S, and Levine MM
- Subjects
- Administration, Oral, Antigens, Bacterial administration & dosage, Antigens, Bacterial adverse effects, Humans, Lymphocyte Activation, Polysaccharides, Bacterial administration & dosage, Polysaccharides, Bacterial adverse effects, Typhoid Fever immunology, Typhoid Fever prevention & control, Typhoid-Paratyphoid Vaccines administration & dosage, Typhoid-Paratyphoid Vaccines adverse effects, Vaccination, Vaccines, Attenuated administration & dosage, Vaccines, Attenuated adverse effects, Antibodies, Bacterial blood, Antigens, Bacterial immunology, Polysaccharides, Bacterial immunology, Salmonella typhi immunology, Typhoid-Paratyphoid Vaccines immunology, Vaccines, Attenuated immunology
- Abstract
Protection against typhoid fever might be best achieved by a vaccine that stimulates IgG antibody to Vi capsular polysaccharide (Vi) in serum, IgG antibody to O antigen in serum, and cell-mediated immune responses. Live typhoid vaccines have not elicited anti-Vi antibody, presumably because Vi expression is highly regulated. CVD 909 is an oral attenuated typhoid vaccine candidate that is engineered to constitutively express Vi. In the present study, CVD 909, at doses of 10(6-9) cfu, was orally administered to 32 healthy adults, and immune responses were measured. Although many of the volunteers generated antibody-secreting cell responses to Vi, only 2 of the 32 volunteers generated anti-Vi IgG antibody in serum.
- Published
- 2004
- Full Text
- View/download PDF
46. Mitogenicity of the recombinant mycobacterial 27-kilodalton lipoprotein is not connected to its antiprotective effect.
- Author
-
Hovav AH, Davidovitch L, Nussbaum G, Mullerad J, Fishman Y, and Bercovier H
- Subjects
- Acylation, Animals, Antigens, Bacterial adverse effects, Antigens, Bacterial immunology, B-Lymphocytes immunology, Cell Line, Female, Humans, Immunization, Lipoproteins adverse effects, Lipoproteins immunology, Lymphocyte Activation immunology, Macrophages, Peritoneal immunology, Membrane Glycoproteins metabolism, Mice, Mice, Inbred BALB C, Mice, Inbred C3H, Mice, Nude, Mycobacterium tuberculosis pathogenicity, Receptors, Cell Surface metabolism, Recombinant Proteins adverse effects, Recombinant Proteins immunology, T-Lymphocytes immunology, Toll-Like Receptor 2, Toll-Like Receptors, Tuberculosis immunology, Tuberculosis prevention & control, Tuberculosis Vaccines administration & dosage, Tuberculosis Vaccines adverse effects, Tuberculosis Vaccines immunology, Antigens, Bacterial pharmacology, Lipoproteins pharmacology, Lymphocyte Activation drug effects, Mycobacterium tuberculosis immunology, Recombinant Proteins pharmacology
- Abstract
We reported previously that even though immunization with the recombinant mycobacterial 27-kDa lipoprotein (r27) induced a Th1-type response in mice, the vaccinated mice became more susceptible to challenge with Mycobacterium tuberculosis. In this study we show that r27 stimulates naive splenocytes to proliferate. Acylation of r27 was crucial for this effect, since a nonacylated mutant of r27, termed r27DeltaSP, failed to stimulate splenocytes either in vitro or in vivo. Depletion experiments indicated that only B cells were proliferating in a T-cell-independent manner. We also found that r27 is recognized by TLR2, which is involved in mitogenic stimulation. Interestingly, r27 but not r27DeltaSP induced high gamma interferon levels in splenocyte supernatants, whereas no significant interleukin-2 levels were detected. Since B-cell polyclonal activation might aggravate pathogen infection, we asked whether the antiprotective effect of the r27 lipoprotein is associated with its mitogenicity. We showed that, as in the case of r27, immunization of mice with the nonmitogenic r27DeltaSP lipoprotein resulted in increased M. tuberculosis multiplication. We conclude that the antiprotective effect of the r27 lipoprotein must be linked to properties of the polypeptide portion of the lipoprotein rather than to its lipid moiety and its mitogenicity.
- Published
- 2004
- Full Text
- View/download PDF
47. Cytokine-chemokine networks in experimental mycobacterial and schistosomal pulmonary granuloma formation.
- Author
-
Chiu BC, Freeman CM, Stolberg VR, Komuniecki E, Lincoln PM, Kunkel SL, and Chensue SW
- Subjects
- Animals, Antibodies metabolism, Antibodies pharmacology, Antigens, Bacterial adverse effects, Antigens, Helminth adverse effects, Chemokines genetics, Cytokines immunology, Disease Models, Animal, Female, Granuloma drug therapy, Granuloma microbiology, Interferon-gamma immunology, Interferon-gamma metabolism, Interleukins immunology, Interleukins metabolism, Lung microbiology, Lung pathology, Mice, Mice, Inbred CBA, Mycobacterium bovis pathogenicity, Schistosoma mansoni pathogenicity, Schistosomiasis mansoni pathology, Th1 Cells metabolism, Th2 Cells metabolism, Transcription, Genetic, Tuberculosis pathology, Chemokines metabolism, Cytokines metabolism, Granuloma metabolism, Schistosomiasis mansoni metabolism, Tuberculosis metabolism
- Abstract
Type-1 and type-2 lung granulomas, respectively, elicited by bead immobilized Mycobacteria bovis and Schistosoma mansoni egg antigens (Ags) display different patterns of chemokine expression. This study tested the hypothesis that chemokine expression patterns were related to upstream cytokine signaling. Using quantitative transcript analysis, we defined expression profiles for 16 chemokines and then examined the in vivo effects of neutralizing antibodies against interferon-gamma (IFN-gamma), interleukin (IL)-4, IL-10, IL-12, and IL-13. Transcripts for CXCL2, -5, -9, -10, and -11 and the CCL chemokine, CCL3, and lymphotactin (XCL1), were largely enhanced by Th1-related cytokines, IFN-gamma or IL-12. Transcripts for CCL11, CCL22, CCL17, and CCL1 were enhanced largely by Th2-related cytokines, IL-4, IL-10, or IL-13. Transcripts for CCL4, CCL2, CCL8, CCL7, and CCL12 were potentially induced by either Th1- or Th2-related cytokines, although some of these showed biased expression. IFN-gamma and IL-4 enhanced the greatest complement of transcripts, and their neutralization had the greatest anti-inflammatory effect on type-1 and type-2 granulomas, respectively. Th1/Th2 cross-regulation was evident because endogenous Th2 cytokines inhibited type-1, whereas Th1 cytokines inhibited type-2 biased chemokines. These findings reveal a complex cytokine-chemokine regulatory network that dictates profiles of local chemokine expression during T cell-mediated granuloma formation.
- Published
- 2003
- Full Text
- View/download PDF
48. Oral immunization of adult volunteers with microencapsulated enterotoxigenic Escherichia coli (ETEC) CS6 antigen.
- Author
-
Katz DE, DeLorimier AJ, Wolf MK, Hall ER, Cassels FJ, van Hamont JE, Newcomer RL, Davachi MA, Taylor DN, and McQueen CE
- Subjects
- Administration, Oral, Adolescent, Adult, Antibodies, Bacterial analysis, Antigens, Bacterial adverse effects, Capsules, Escherichia coli metabolism, Escherichia coli Proteins adverse effects, Escherichia coli Vaccines adverse effects, Female, Humans, Immunity, Cellular, Immunization, Immunoglobulin A blood, Immunoglobulin G blood, Male, Middle Aged, Vaccines, Synthetic administration & dosage, Vaccines, Synthetic immunology, Vaccines, Synthetic therapeutic use, Antigens, Bacterial administration & dosage, Antigens, Bacterial immunology, Bacterial Toxins administration & dosage, Bacterial Toxins immunology, Enterotoxins administration & dosage, Enterotoxins immunology, Escherichia coli immunology, Escherichia coli Proteins administration & dosage, Escherichia coli Proteins immunology, Escherichia coli Vaccines administration & dosage, Escherichia coli Vaccines immunology
- Abstract
As a step in the development of an oral vaccine against ETEC, we evaluated the safety and immunogenicity of CS6, a polymeric protein commonly found on the surface of ETEC. Formulations included 1 and 5mg doses of CS6, either encapsulated in biodegradable polymer poly(D, L)-lactide-co-glycolide (PLG), or as free protein, administered orally in a solution of either normal saline or a rice-based buffer. Three doses of CS6 were given at 2-week intervals. Blood was collected immediately before and 7 days after each dose. All formulations were well tolerated. Four of five volunteers who received 1mg CS6 in PLG microspheres with buffer had significant IgA ASC responses (median=30 ASC per 10(6) PBMC) and significant serum IgG responses (median=3.5-fold increase). Oral administration of these prototype ETEC vaccine formulations are safe and can elicit immune responses. The ASC, serum IgA, and serum IgG responses to CS6 are similar in magnitude to the responses after challenge with wild-type ETEC [Coster et al., unpublished data]. Further studies are underway to determine whether these immune responses are sufficient for protection.
- Published
- 2003
- Full Text
- View/download PDF
49. Effect of monophosphoryl lipid A (MPL) on T-helper cells when administered as an adjuvant with pneumocococcal-CRM197 conjugate vaccine in healthy toddlers.
- Author
-
Vernacchio L, Bernstein H, Pelton S, Allen C, MacDonald K, Dunn J, Duncan DD, Tsao G, LaPosta V, Eldridge J, Laussucq S, Ambrosino DM, and Molrine DC
- Subjects
- Adjuvants, Immunologic adverse effects, Aluminum Compounds administration & dosage, Aluminum Compounds adverse effects, Aluminum Compounds immunology, Aluminum Compounds pharmacology, Antibodies, Bacterial biosynthesis, Antigens, Bacterial administration & dosage, Antigens, Bacterial adverse effects, Antigens, Bacterial immunology, Bacterial Proteins adverse effects, Bacterial Proteins immunology, Child, Preschool, Cytokines biosynthesis, Female, Humans, Immunity, Cellular drug effects, Immunity, Cellular immunology, Immunoglobulin G biosynthesis, Infant, Lipid A adverse effects, Lipid A immunology, Lymphocyte Activation drug effects, Lymphocyte Activation immunology, Male, Phosphates administration & dosage, Phosphates adverse effects, Phosphates immunology, Phosphates pharmacology, Polysaccharides, Bacterial adverse effects, Polysaccharides, Bacterial immunology, T-Lymphocyte Subsets drug effects, T-Lymphocyte Subsets immunology, T-Lymphocyte Subsets metabolism, T-Lymphocytes, Helper-Inducer metabolism, Vaccines, Conjugate administration & dosage, Vaccines, Conjugate adverse effects, Vaccines, Conjugate immunology, Vaccines, Synthetic administration & dosage, Vaccines, Synthetic adverse effects, Vaccines, Synthetic immunology, Adjuvants, Immunologic administration & dosage, Bacterial Proteins administration & dosage, Lipid A administration & dosage, Lipid A analogs & derivatives, Polysaccharides, Bacterial administration & dosage, T-Lymphocytes, Helper-Inducer immunology
- Abstract
As new vaccines are developed, novel adjuvants may play an important role in eliciting an effective immune response. We evaluated the safety and adjuvant properties of monophosphoryl lipid A (MPL in 129 healthy toddlers immunized with two doses of nine-valent pneumococcal-CRM(197) protein conjugate vaccine (PCV9) combined with 10, 25, or 50 micro g of MPL with or without alum (AlPO(4)). Vaccine-specific humoral and cell-mediated responses were examined following the second dose of study vaccine. All doses of MPL were well-tolerated and a dose-dependent effect of MPL on specific cellular responses was observed. The 10 micro g MPL dose significantly enhanced CRM(197)-specific T-cell proliferation (P=0.02) and interferon-gamma (INF-gamma) production (P=0.009) compared to responses of controls who received PCV9 with AlPO(4). In contrast, CRM(197)-specific T-cell proliferation and interferon-gamma production of the 50 micro g MPL/AlPO(4) group were decreased when compared to controls although these differences did not reach statistical significance. IL-5 and IL-13 responses after immunization showed a similar pattern with increased production in the 10 micro g MPL group and decreased production in the 50 micro g MPL/AlPO(4) group compared to controls. There were no differences in serum IgG antibody concentrations to the nine vaccine pneumococcal capsular polysaccharides and carrier protein between the MPL-containing and control vaccine groups. These findings demonstrate a dose-dependent effect of MPL on T-helper cell type 1 (TH-1) responses to the carrier protein and also suggest an effect on T-helper cell type 2 (TH-2) responses.
- Published
- 2002
- Full Text
- View/download PDF
50. Mucosal administration of heat shock protein-65 decreases atherosclerosis and inflammation in aortic arch of low-density lipoprotein receptor-deficient mice.
- Author
-
Maron R, Sukhova G, Faria AM, Hoffmann E, Mach F, Libby P, and Weiner HL
- Subjects
- Administration, Intranasal, Administration, Oral, Animals, Antibodies, Bacterial blood, Antigens, Bacterial administration & dosage, Antigens, Bacterial adverse effects, Aorta, Thoracic metabolism, Aorta, Thoracic pathology, Arteriosclerosis immunology, Arteriosclerosis pathology, Cell Count, Cell Division drug effects, Cell Division immunology, Chaperonin 60, Chaperonins adverse effects, Chaperonins immunology, Cholesterol, Dietary, Cytokines metabolism, Female, Freund's Adjuvant administration & dosage, Inflammation pathology, Lymph Nodes metabolism, Macrophages drug effects, Macrophages pathology, Mice, Mice, Inbred C57BL, Mice, Knockout, Mycobacterium immunology, Nasal Mucosa cytology, Nasal Mucosa drug effects, Nasal Mucosa metabolism, Receptors, LDL genetics, Spleen cytology, Spleen drug effects, Spleen immunology, T-Lymphocytes drug effects, T-Lymphocytes pathology, Aorta, Thoracic drug effects, Arteriosclerosis prevention & control, Bacterial Proteins, Chaperonins administration & dosage, Inflammation prevention & control, Receptors, LDL deficiency
- Abstract
Background: Increasing evidence supports the involvement of inflammation and immunity in atherogenesis as well as the role of autoimmunity to heat shock proteins (HSPs) in the progression of atherosclerosis. Mucosal administration of autoantigens decreases organ-specific inflammation and disease in several models of autoimmunity (diabetes, arthritis, and encephalomyelitis) and is also being tested in human clinical trials., Methods and Results: We examined the effect of nasal or oral administration of mycobacterial HSP-65 on atherosclerotic lesion formation in mice lacking the receptor for LDL that were maintained on a high-cholesterol diet. Animals were nasally or orally treated for 1 week with HSP-65, and a high-cholesterol diet was started after the last treatment. The mice were mucosally treated once a week for 8 or 12 weeks, at which time pathological analysis was performed. We found a significant decrease in the size of atherosclerotic plaques, a reduction in macrophage-positive area in the aortic arch, increased interleukin-10 expression, and a reduced number of T cells in nasally treated animals compared with control animals. A similar trend was observed in orally treated mice, but it was not significant., Conclusions: Our results demonstrate that nasal vaccination with HSP reduces the inflammatory process associated with atherosclerosis and provides a new immunologic approach for the treatment of atherosclerosis.
- Published
- 2002
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.